
Professor Andrew Zannettino
Executive Dean
Health and Medical Sciences Faculty Office
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Andrew is the Executive Dean of the Faculty of Health and Medical Sciences at the University of Adelaide.
Prior to commencing as Executive Dean, Andrew held the positions of Pro Vice-Chancellor of Health Partnerships (University of Adelaide) and Executive Director of Research Strategy (Central Adelaide Local Health Network).
Andrew is a Professor of Experimental Haematology and co-directs the Myeloma Research Laboratory within the Precision Cancer Medicine Theme at the South Australian Health and Medical Research Institute (SAHMRI). He is a recognised leader in the field of mesenchymal stem cell biology and holds numerous patents covering the composition and regenerative properties of Mesenchymal Precursor Cells (MPCs), a rare cell population present in many postnatal tissues. The family of patents underpin the cell therapy company, Mesoblast Ltd.
Andrew is a founding member of the Medical and Scientific Advisory Group (MSAG) of Myeloma Australia, the peak body in Australian focused on PBAC submissions, guidance documents and advocacy for myeloma. He, additionally, serves as non-executive director of AusHealth Pty Ltd and a member of a number of intramural and extramural boards.
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
Research Interests
Myeloma and Bone Cancer Research
Multiple myeloma is haematological malignancy characterised by the clonal proliferation of plasma cells, an immune cell type that normally protects us against infection. Myeloma is the second most common blood cancer and more than 140,000 people are diagnosed each year worldwide. Despite recent advances in treatment, myeloma remains universally fatal and has a 10-year survival rate of approximately 28%. The main clinical manifestations of myeloma are the development of osteolytic bone lesions, bone pain, hypercalcaemia, renal insufficiency, suppressed immunoglobulin production and increased bone marrow angiogenesis (blood vessel formation). Myeloma is preceded by a premalignant (asymptomatic) monoclonal gammopathy of uncertain significance (MGUS) stage. The factors that trigger the progression from MGUS to myeloma remain to be determined; however, our studies show that both intrinsic genetic changes and extrinsic factors play a role in disease progression. The Myeloma Research Laboratory’s research is focussed on detecting the key signalling pathways that are deregulated during disease development and determining what microenvironmental changes occur during disease pathogenesis. We believe that these approaches will enable us to identify new molecular markers of disease risk and to design drugs against novel therapeutic targets.
The MRL has made, and continues to make significant contributions to the field through ongoing projects in:
- Identifying the mechanisms of myeloma associated bone loss
- Identifying the genetic, transcriptional and epigenetic changes that trigger the progression from asymptomatic MGUS to myeloma
- Determining why the bone marrow is a “hot-spot” for myeloma plasma cell metastasis
- Identifying the mechanisms governing dissemination and relapse in multiple myeloma
- Identifying how myeloma plasma cells affect mesenchymal stem cell differentiation.
- The use of single cell sequencing to discover tumour-associated changes in the bone microenvironment of myeloma patients: identification of prognostic markers and novel therapeutic targets
- The use of high-precision proteomics to identify novel serum biomarkers to identify high-risk smouldering myeloma patients prior to progression to active multiple myeloma
- Identifying a role for the mTOR pathway in mesenchymal stem cell biology and bone formation.
- Assessing the effectiveness of targeting skeletal mTORC1 as a novel approach to treat diet-induced insulin resistance
Therapeutic Use of Mesenchymal Progenitor Cells
Mesenchymal Progenitor Cells (MPC) are rare stem cells present within post-natal tissues which possess promising therapeutic properties. In the late 90’s, collaborative studies in association with Professor Stan Gronthos (Mesenchymal Stem Cell Laboratory, UA/SAHMRI) and Professor Paul Simmons (Mesoblast Ltd.) led to the patenting of technologies covering the identification and isolation of these rare cells from bone marrow. The family of patents surrounding this technology were assigned to Angioblast Systems Inc., New York, USA in November 2004 facilitating the formation of Mesoblast Ltd, an Australian Stock Exchange listed company (http://www.mesoblast.com). In return for the assignment of these patents, the IMVS/Medvet/SA Pathology (my substantive employer at that time) received a significant parcel of shares in this company. From January 2005 until December 2016, I have served as a consultant to both Angioblast Systems Inc. and Mesoblast Ltd. and continued to receive funding to support the improvement/development of existing/new intellectual property and to fund large pre-clinical animal models of disease.
Research Collaborations
My expertise in the fields described above has led to active collaborations with scientists/clinicians throughout the world as detailed below.
In 1994-1995, I developed a powerful retroviral-based expression cloning strategy to enable isolation of genes encoding cell surface molecules that participate in intercellular interactions. This methodology has led to numerous collaborations and ongoing consultation work with scientists including:
- Dr H-J. Buhring, University of Tubingen, Germany. Retroviral Expression cloning of cell surface antigens expressed by normal and leukaemic haemopoietic stem cells;
- Prof. Leonie K. Ashman, University of Newcastle. Retroviral Expression cloning of drug resistance genes;
- Prof. James T. Triffit, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, UK. Retroviral Expression cloning of osteoblast-related cell surface antigens;
- Dr S. Watt, MRC Molecular Haematology Unit, The Institute of Molecular Medicine, University of Oxford, UK. Retroviral Expression cloning of novel cell surface molecules.
My research into myeloma-associated bone loss and molecular mechanisms of myeloma disease pathogenesis has led to further collaborations with a number of academic and industry-based scientists including:
- Prof. John Shaughnessy, Formerly of University of Arkansas, Little Rock, Arkansas, USA and founder of SignalGeneticsTM, Carlsbad, CA. The role of DKK-1 in myeloma-associated bone loss;
- Dr Daniel Peet, Department of Bichemistry, Molecular Life Sciences, University of Adelaide: Role of CXCL12 (SDF-1)/CXCR4 in Pathological Angiogenesis and Osteolytic Bone Disease in Multiple Myeloma;
- Dr Phil Kearney, Santaris Pharma, Copenhagen, Denmark: Role of CXCL12 (SDF-1)/CXCR4 in Pathological Angiogenesis and Osteolytic Bone Disease in Multiple Myeloma;
- Prof. Nobutaka Fujii and Prof. Hirokazu Tamamura, Graduate School of Pharmaceutical Sciences Kyoto University Department of Bioorganic Medicinal Chemistry, JAPAN, Role of SDF-1 in myeloma;
- A/Prof. Kevin Lynch, Novartis, Sydney, Australia, Tyrosine Kinase Inhibition as a Potential Modality to Control Osteolytic Bone Disease: A New Role for Imatinib Mesylate and Second Generation Bcr-Abl Inhibitors;
- Dr Elisabeth Buchdunger and Dr Paul Manley, Novartis Pharma, Skeletal Effects of the Abl Kinase Inhibitors, Nilotinib and Imatinib;
- Dr Francis Lee and Dr Richard Smykla, Bristol-Myers Squibb, Skeletal Effects of the Abl Kinase Inhibitors, Dasatinib;
- Prof. Vijay Modur, Novartis Pharmaceuticals Corporation, Cambridge, MA, USA. Novel mediators of multiple myeloma metastases to the bone;
- Prof. William Dougall, Amgen, Seattle, Washington, USA, The role of RANKL in myeloma-associated bone loss;
- Dr Daniela Niepel, Global Medical Executive Director, Amgen GmbH, Rotkreuz, Switzerland. The application of bone targeting agents (BTA) in oncology.
- Prof. Peter Croucher, Bone Biology Laboratory, Bone Biology Division, Garvan Institute of Medical Research, NSW, AUS. The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Dr Daniel Worthley, University of Adelaide, Adelaide, Australia, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Prof. Siddhartha Mukherjee, Columbia University, NY, USA. The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Prof. Orest Blaschuk, Urology Research Laboratories, Division of Urology, McGill University Health Centre, Canada and Zonula Inc. The use of Cadherin antagonists to treat multiple myeloma;
- Prof. Jonathan Licht, University of Florida Cancer Centre. The role of EMT in myeloma disease dissemination and disease progression;
- Prof. Ricky Johnstone, Gene Regulation Laboratory, Peter MacCallum Cancer Centre, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Associate Professor Simon Leedham, Wellcome Trust Centre for Human Genetics, Oxford, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Prof. Charles Mullighan, Hematological Malignancies Program, St. Jude Children’s Research Hospital, Understanding clonal evolution in multiple myeloma;
- Dr Gareth Davies, Senior Research Scientist / Project Leader, UCB Celltech – New Medicines, Slough, UK. Targeting stromal derived Gremlin 1 as a novel therapeutic modality to treat multiple myeloma
- Prof. Gareth Morgan, University of Arkansas, Myeloma Institute for Research and Therapy (UAMS), Understanding clonal evolution in multiple myeloma.
- Prof. Tilman Brummer, Institute of Molecular Medicine and Cell Research Albert-Ludwigs University of Freiburg, Germany. The role of the novel tumour suppressor gene, SAMSN1, in the pathogenesis and metastasis of multiple myeloma.
My research into physiological and aberrant bone remodelling and novel skeletally-derived factors that regulate glucose metabolism has led to collaborations with a number of academic and industry-based scientists including:
- Prof. D.M. Findlay, Dr Gerald J. Atkins and Dr. Andreas Evdokiou, Discipline of Orthopaedics and Trauma, Royal Adelaide Hospital and the University of Adelaide. Normal and pathological bone remodelling;
- Dr Colin Dunstan, University of Sydney and formerly of Amgen Inc, CA, USA; The Role of OPG in bone metabolism;
- A/Prof Barry C Powell, Dr Peter J Anderson and Prof David David, Child Health Research Institute and The Women’s and Childrens Hospital, Adelaide, South Australia: Mechanisms of premature cranial fusion and development of novel adjunct approaches to treatment;
- Prof H. Zreiqat, School of Pathology, University of New South Wales, Sydney, Australia. Behaviour of osteoclasts and bone cells on bio-material surfaces;
- Prof D. R. Haynes, Department of Pathology, University of Adelaide, Adelaide, South Australia. The role of TNF family members TWEAK and TNF-alpha in bone remodelling;
- A/Prof Sofianos Andrikopoulos, The University of Melbourne, The University of Melbourne. Skeletal endocrine signalling in the regulation of glucose metabolism;
- Dr Paul Baldock, Garvan Institute of Medical Research, Garvan Institute of Medical Research. The University of New South Wales, Skeletal endocrine signalling in the regulation of glucose metabolism;
- Christopher Proud, South Australian Health and Medical Research Institute, SA, AUS. Targeting skeletal mTORC1 as a novel approach for the treatment of diet-induced insulin resistance.
- William Cawthorn, University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, Edinburgh, Scotland. The role of raptor/mTORC1 and bone marrow adipose tissue (BMAT) in the control of whole-body glucose metabolism
My research into mesenchymal precursor cell biology and application has led to collaborations with a number of biotechnology companies, including Angioblast Systems Inc., Mesoblast Ltd. and Genzyme International. In addition, I also collaborate and consult for a number of academic scientists including:
- Prof. Silviu Itescu, Mesoblast Ltd.: Clinical Application of Mesenchymal Precursor Cells for bone repair, articular cartilage regeneration, disc cartilage regeneration, cellular therapy of heart attack/heart failure, peripheral arterial disease and wound ulcers;
- A/Prof. Robert Moore, formerly head of the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science, Adelaide, South AUSTRALIA: A Preclinical trial of the potential for cultured mesenchymal precursor cells to restore extracellular matrix and normal mechanical function to degenerate intervertebral discs;
- Prof. Peter Ghosh, Institute of Nutraceutical Research, Brookevale, NSW, Australia: Cartilage Regenerative Potential of Ovine Mesenchymal Precursor Cells (MPC);
- A/Prof John Field, Flinders University of South Australia, School of Medicine, Bedford Park, South Australia: Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPC) for the repair of critical size defects in an ovine tibial model;
- Prof. Stephen Worthley, formerly Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, South Australia: A study of the cardiac regenerative potential of immunoselected ovine bone marrow mesenchymal stem cells;
- Dr Cory Xian and Prof. Bruce Foster, Bone Growth Foundation, University of South Australia and Department of Orthopaedic Surgery, Women's and Children's Hospital. Molecular pathways for the bony repair of injured growth plate cartilage;
- Prof. Richard Harvey and Professor Robert Graham, Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia. Identification of endogenous cardiomyogenic stem cells.
From 2005 to 2016, I served as a scientific consultant for Mesoblast Ltd. where I helped to consolidate and expand our stem cell-based technology patent family and successfully completed key milestones such as the development of GMP-grade MPC isolation and culture expansion standard operational protocols. This resulted in an increase in capital investment to support the commencement of several phase II/III cardiac and orthopaedic clinical studies. Funds from Mesoblast Ltd were used to continue basic R&D in our laboratory and for initiating new pre-clinical animal studies within the IMVS/ Hanson Institute/ RAH/ University of Adelaide campuses. Collectively, these studies formed the foundation of new IND (investigative new drug) applications submissions to the USA FDA for future phase I/II/III human clinical trials involving different health centres and laboratories in Adelaide, Australia and the USA.
Research Output
I have co-authored more than 300 refereed publications, book chapters and review articles (not including published abstracts). Many of these articles are published in premier Haematology and Orthopaedic journals (BLOOD, Leukemia, BJH, JBMR, Bone), Cancer journals (Cancer Research, Clinical Cancer Research) and Stem Cell journals (Cell Stem Cell, Stem Cells). My publications have received in excess of 17,000 citations and my H Factor = 73. Refer to Publications section for full details.
Presentations
I have been invited to present my laboratory’s findings at more than 45 national and international forums since 2010. In addition, I have co-authored more than 100 abstracts with more than 60 of these being published as Meeting Proceedings.
Year | National/ International | Event Title | Role |
---|---|---|---|
2018 | International | The Myeloma 2018 Workshop, San Diego, CA, USA | Invited Speaker |
2017 | National | Monash Haematology Seminar Series, Victoria, Australia | Invited Speaker |
2016 | National | Translating Research for Impact: Strategies for Success, Adelaide, Australia | Invited Speaker |
2016 | National | Inaugural National Myeloma Workshop, Yarra Valley, Victoria, Australia | Invited Speaker |
2016 |
National |
New Directions in Leukaemia Research meeting March 16-19, 2016, Noosa, QLD, AUS |
Invited Speaker |
2015 |
International |
"PACIFICHEM 2015 Conference December 15-20, 2015 in Honolulu, HI." |
Invited Speaker |
2014 |
International |
American Society of Haematology |
Invited Speaker |
2014 |
National |
Sydney Cancer and Bone Meeting |
Invited Speaker |
2013 |
International |
Australian and New Zealand Bone and Mineral Society |
Invited Speaker |
2013 |
National |
Frontiers in Skeletal Biology |
Invited Speaker |
2012 |
National |
Combio 2012 |
Invited Speaker |
2012 |
National |
SA Multiple Myeloma Interest Group |
Invited Speaker |
2012 |
National |
SVRI-Seminar Series |
Invited Speaker |
2012 |
National |
The Australian Health and Medical Research Congress |
Invited Speaker |
2011 |
International |
Austalian and New Zealand Bone and Mineral Research |
Plenary Speaker |
2010 |
National |
Adelaide Bone Group Meeting |
Invited Speaker |
2010 |
International |
American Society of Haematology |
Session Chair |
2010 |
National |
Annual HSANZ - SA “Blood Club Meeting”, |
Invited Speaker |
2010 |
National |
Leukaemia Foundation of Australia – Myeloma Awareness Day |
Invited Speaker |
2009 |
International |
Asia Pacific Haematology Summit |
Keynote Speaker |
2009 |
International |
HAA 2009; 2009 Annual Scientific Meeting of HSANZ, ANZSBT, ASTH |
Keynote Speaker |
2009 |
National |
Health Development Adelaide Symposium |
Presenter |
2009 |
International |
Janssen Cilag, Multiple Myeloma 3 (MM3) meeting |
Presenter |
2009 |
International |
Novartis APECHO-APTM Workshop |
Keynote Speaker |
2008 |
International |
American Society of Haematology |
Poster Presenter |
2008 |
National |
Bio Innovation SA Networking Forum – Bio Innovation Osteo Networking Evening |
Keynote Speaker |
2008 |
International |
Fifth Clare Valley Bone Meeting |
Keynote Speaker |
2008 |
National |
NCRIS 5.5 CGMP - SEMINAR/WORKSHOP - “NANO-ENGINEERING FOR CELLS” |
Presenter |
2008 |
National |
Royal Adelaide Hospital Medical Grand Round |
Presenter |
2007 |
National |
Barbara Ell Seminar Series, Victor Chang Cardiac Research Institute |
Presenter |
2007 |
International |
Novartis Oncology Research and Development Symposium |
Presenter |
2007 |
National |
2007 Mater Medical Research Institute Symposium |
Presenter |
2006 |
International |
American Society of Haematology |
Session Chair |
2006 |
National |
Department of Orthopaedics and Trauma, Royal Melbourne Hospital |
Presenter |
2006 |
National |
Inaugural Tissue Engineering Symposium (SuTEN), Biomedical Engineering at Sydney University School of Aerospace, Mechanical and Mechatronic Engineering and The Bosch Institute |
Presenter |
2006 |
International |
Novartis Oncology Australia, Research and Development Symposium, The Intercontinental Hotel |
Keynote Speaker |
2005 |
National |
ANZ Matrix Biology Society Conference, Whalers Inn, Victor Harbour, SA |
Keynote Speaker |
2005 |
National |
Department of Genetic Medicine, Womens and Children’s Hospital |
Presenter |
2005 |
National |
Division of Molecular Pathology, IMVS |
Presenter |
2005 |
National |
The Basil Hetzel Institute, The Queen Elizabeth Hospital |
Presenter |
2004 |
International |
Haematology Society of Australia and New Zealand, Exhibition and Convention Centre |
Presenter |
2003 |
National |
Adelaide Blood Club |
Invited Speaker |
2003 |
National |
Division of Clinical Biochemistry, IMVS |
Invited Speaker |
2003 |
National |
Division of Molecular Pathology, IMVS |
Invited Speaker |
2003 |
National |
Division of Pathology, IMVS |
Invited Speaker |
2003 |
National |
The Alfred Hospital |
Invited Speaker |
2002 |
International |
Australian and New Zealand Orthopaedic Research Society |
Invited Speaker |
2002 |
National |
Child Health Research Institute |
Invited Speaker |
2002 |
National |
Department of Medicine, University of Adelaide |
Invited Speaker |
2002 |
National |
Molecular Biology of Skeleton |
Invited Speaker |
2001 |
National |
Adelaide Blood Club |
Invited Speaker |
2001 |
International |
Molecular Mechanisms of Skeletal Disease mediated by Myeloma, NIH |
Invited Speaker |
2001 |
International |
Zymogenetics |
Invited Speaker |
1998 |
International |
Australian and New Zealand Orthopaedic Research Society |
Invited Speaker |
1998 |
International |
Haematology Society of Australia and New Zealand |
Invited Speaker |
1998 |
National |
Hanson Symposium |
Invited Speaker |
Additional Evidence of Research Leadership
When I joined the UA School of Medical Sciences (SoMS), I served as a member of the Research Committee. In January 2014, I was appointed as Chair of this committee, and immediately instituted 4 new funding programs designed to drive research activity, including an ECR “kick start” award, a strategic equipment fund, an ECR/MCR travel award and a publication award program.
I was also appointed to the SoMS board, the FHMS Research Committee and was the Deputy Chair of the Adelaide Medical and Nursing School (AMNS) Project Committee overseeing the construction of a new $246 million Medical/Nursing/Research facility in the new West End Biomedical Research Precinct which will house approximately 650 Researchers. In January 2015, I was appointed to Deputy Head od School, SoMS. In March 2015, the Executive Dean, Professor Alastair Burt appointed me to establish and chair the Research Strategy Taskforce (RSTF). The RSTF was charged with the responsibility of devising a new research strategy to promote research excellence within the FHMS. This work led to the development of an adaptable strategic framework to enhance research education (HDR/honours), develop research strengths, build enabling technologies/research infrastructure and develop pathways to improved health care and the generation of valuable intellectual property.
My national standing in the fields of cell and cancer biology has been recognised by my appointment to the NHMRC Grant Review Panel (GRP) for Cell biology (2005, 2006) and Oncology (2010) and Assigners Academy (2014-2018). In recognition of my international standing in the field of myeloma-associated bone loss, I was invited by the Leukaemia Research Fund (LRF) of UK, to participate in a “site visit” of Myeloma Program of Prof. Peter Croucher, University of Sheffield, UK, to assess his application for program funding through the LRF in both 2006 and 2009. In addition, I was invited to participate as a moderator for the 2006 American Society of Haematology (ASH) Annual Meeting, for the session titled “Multiple Myeloma: Microenvironment”. I was invited to be an Abstract Reviewer of the “Myeloma-Pathophysiology and Preclinical studies excluding Therapy” Category for the 52nd Annual Meeting of the ASH, a prestigious appointment bestowed upon recognized experts in the field.
As a testament to my expertise in my chosen fields, I have been asked to present my laboratory's findings at numerous scientific meetings and institutions (see “Conference Presentations”) and I have been asked to contribute to numerous review articles and book chapters (see “Publications”). As a recognised expert in the areas of skeletal, stem and cancer biology, I am asked to review >3 manuscripts per month for more than 20 journals including BLOOD, Leukemia, Leukemia and Lymphoma, Experimental Hematology, Haematologica, Journal of Bone and Mineral Research, Leukemia, Cell Stem Cell, Clinical Cancer Research, Cancer Research, International Journal of Cancer, Bone, FASEB Journal. I am also regularly asked to review applications for a number of funding bodies including the NHMRC, Cancer Council of South Australia, Cure Cancer Australia, Leukaemia Research Fund (UK), The Health Research Board (HRB) of Ireland, Singapore Ministry of Education and the Research Grants Council (RGC) of Hong Kong. I was approached by the Wiley-Blackwell publishing house to assess the merits of publication of a book entitled: “Stem Cells: Science and Business Strategies” by A. Vertes et al.
As further evidence of my scientific standing, I have served on organising committees involved in staging both national and international scientific meetings including; the 2004 Hanson Symposium Stem Cell Meeting (Adelaide, SA, 2004); the 10th International Myeloma Congress (Sydney, NSW, 2005); the Clare Bone Meeting (Clare Valley, SA, 2006) and the Australian Myeloma Workshop (2016). I was a member of a committee comprised of stakeholders for the Commonwealth's $35 million Super Science Initiative (SSI) - Translating Health Discovery (THD) and represent the Centre for Cancer Biology (CCB) as a Subject Matter Expert (SME) charged with the role of identifying the facilities requirements for the South Australian Health and Medical Research Institute (SAHMRI). Finally, I have served on the Fellowships and Scholarships Committee for the Leukaemia Foundation of Australia.
Clinical Outcomes of Research
As a member of MSAG, I have provided guidance on both myeloma and supportive treatment strategies and have co-authored guidelines for the safe use of bisphosphonates and Clinical Practice Guidelines. Furthermore, my work has raised the awareness amongst clinicians of the importance of routine examination of CTX levels in patients. CTX (the C-telopeptide of the α1 chain of collagen type 1), a reliable marker of bone turnover, is now being used locally as a routine test for all myeloma patients at diagnosis and restaging. CTX, when used in conjunction with paraprotein levels and bone marrow assessment can detect early progression of myeloma. This is a palpable achievement and one that has led to better outcomes for patients.
As a co-inventor of the Mesenchymal Progenitor Cell (MPC) cellular therapy, I have been instrumental in developing a therapy that is likely to have a significant impact in the areas of spinal fusion, osteoarthritis, congestive heart failure, heart attacks, eye diseases, diabetes, and bone marrow repair.
Patents
I am a co-inventor of patents that describe the isolation and composition of matter of mesenchymal precursor cells (MPC), a unique population of adult stem cells with tissue reparative properties. This family of patents were assigned to Angioblast Systems Inc., New York, USA in November 2004 facilitating the formation of Mesoblast Ltd, an Australian Stock Exchange listed company. In 2010, Mesoblast acquired Angioblast Systems Inc forming the Mesoblast Group.
Initial Patents Assigned to Angioblast Systems Inc. Leading to formation of Mesoblast Ltd.
Patent: WO 01/04268 A1: AUSTRALIA, 1999
Status: Granted
Inventors: Paul Simmons, Andrew Zannettino, Stan Gronthos, Description of patent: Mesenchymal Precursor Cells. Founding patent for the formation of Mesoblast Ltd.
Applicability/Impact: Novel discovery of multi potential stem cells from connective tissue for tissue regeneration. Patent granted in AU, US, CA, ES, EP.
Patent: WO 2004/084921 A1: AUSTRALIA, 2003
Status: Granted
Inventors: Stan Gronthos and Andrew Zannettino.
Description of patent: Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation. Founding patent for the formation of Mesoblast.
Applicability/Impact: The use of stem cells to regenerate blood vessels during tissue regeneration. Patent granted in US, AU, EP, CA, CN, ES.
Patent: WO 2004/085630 A1: AUSTRALIA, 2003
Status: Granted
Registered in names of (Inventors): Stan Gronthos, Andrew Zannettino and Songtao Shi.
Description of patent: Perivascular Mesenchymal Precursor Cells. Founding patent for the formation of Mesoblast Ltd.
Applicability/Impact: Discovery of unique perivascular multi potential stem cell for regeneration of tissue. Patent granted in US, AU, CA, CN.
Patent: WO 2006/032092 A1: UNITED STATES OF AMERICA, 2004
Status: Granted
Inventors: Andrew Zannettino and Stan Gronthos.
Description of patent: Multipotential expanded Mesenchymal Precursor Cell progeny and uses there off. Founding patent for the formation of Mesoblast Ltd.
Applicability/Impact: Discovery of unique multi-potential adult stem cell for tissue regeneration. Patent granted in US, AU, EP, CN.
Patent: WO 2006/032075 A1: AUSTRALIA, 2004
Status: Granted
Inventors: Stan Gronthos and Andrew Zannettino.
Description of patent: Method of enhancing proliferation and/or survival of mesenchymal precursor cells. Founding patent for formation of Mesoblast Ltd.
Applicability/Impact: Novel protocols for developing GMP ex vivo expansion protocols for the manufacture of MPC for clinical use. Patent granted in US, AU, CN.
Supportive Patents Assigned to Mesoblast Ltd.
Patent: PCT/AU2016/050438: AUSTRALIA, 2015
Status: Awarded (PCT)
Inventors: Stan Gronthos, Andrew CW Zannettino, Stephen Fitter.
Description of patent: Methods and Products for Enriching and Isolating Stem Cells. Patent assigned to Mesoblast Ltd.
Applicability/Impact: Identification and characterisation of the STRO-1 antigen a marker of mesenchymal precursor cells. Purification of MPC for clinical applications.
Patent: WO 2010/019997 A1: UNITED STATES OF AMERICA, 2008
Status: Granted
Inventors: Andrew Zannettino and Stan Gronthos
Description of patent: Monoclonal antibody STRO-4 selection of mesenchymal precursor cells. Patent assigned to Mesoblast Ltd.
Applicability/Impact: First reagent for isolation of MPC for pre-clinical ovine and human clinical studies. Patent granted in USA and AU.
Patent: W02006/108229 A1: UNITED STATES OF AMERICA, 2006
Status: Granted
Registered in names of Inventors: Andrew Zannettino, Stan Gronthos and Paul Simmons.
Description of patent: Isolation of adult multipotential Cells by tissue non-specific alkaline phosphatase. Patent assigned to Mesoblast Ltd.
Applicability/Impact: Novel stem cell marker developed into a GMP reagent for clinical human trials. Patent granted in USA, AU, EP, CA, HK.
In addition to the Mesoblast Ltd-related patents, I am also a substantive inventor of the following patents:
Patent: PCT 1809946.5
Status: PCT filed June 2018, UK IPO
Registered in names of Inventors: Gareth Davies (UCB Biopharma SPRL), Andrew Zannettino, Duncan Hewett, Kimberley Clark, Kate Vandyke and Bill Panagopoulos (The University of Adelaide), (Simon Leedham) Oxford University Innovation Limited.
Description of Patent: Prevention and treatment of cancer
Applicability/Impact: Use of Gremlin 1 antagonists to prevent and treat cancer
Patent: PCT/AU2016/050438
Status: Granted
Registered in names of Inventors: Andrew Zannettino, Stephen Fitter, Stan Gronthos
Description of patent: Methods and products for enriching and isolating stem cells. Patent owned by the University of Adelaide.
Applicability/Impact: Describes HSC70 as a stem cell antigen and the use of anti-HSC7 reagents to isolate and enrich for stem cells
Patent granted in USA, AU, EP, CA, HK.
-
Awards and Achievements
Date Type Title Institution Name Country Amount 1999 Award Young Investigator Award Hanson Centre for Cancer Research Australia - 1998 Award Johnson and Johnson Young Investigator award Australian and New Zealand Orthopaedics Research Society Australia - 1992 Award Postgraduate Scholarship Award University of Adelaide Australia - -
Research Interests
-
Journals
Year Citation 2015 Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2015). Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Letters, 357(1), 160-169.
Scopus41 WoS36 Europe PMC342015 Martin, S., Fitter, S., Dutta, A., Matthews, M., Walkley, C., Hall, M., . . . Zannettino, A. (2015). Brief report: The differential roles of mTORC1 and mTORC2 in mesenchymal stem cell differentiation. Stem Cells, 33(4), 1359-1365.
Scopus80 WoS70 Europe PMC692015 Cakouros, D., Isenmann, S., Hemming, S., Menicanin, D., Camp, E., Zannetinno, A., & Gronthos, S. (2015). Novel basic helix-loop-helix transcription factor hes4 antagonizes the function of twist-1 to regulate lineage commitment of bone marrow stromal/stem cells. Stem Cells and Development, 24(11), 1297-1308.
Scopus27 WoS24 Europe PMC262015 Martin, S., Gan, Z., Fitter, S., To, L., & Zannettino, A. (2015). The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma. Leukemia Research, 39(3), 380-387.
Scopus20 WoS18 Europe PMC152015 Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38.
Scopus32 WoS26 Europe PMC282015 Gan, Z., Fitter, S., Vandyke, K., To, L., Zannettino, A., & Martin, S. (2015). The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. European Journal of Haematology, 94(4), 343-354.
Scopus32 WoS28 Europe PMC232015 Gupte, A., Baker, E., Wan, S., Stewart, E., Loh, A., Shelat, A., . . . Walkley, C. (2015). Systematic screening identifies dual PI3K and mTOR Inhibition as a conserved therapeutic vulnerability in osteosarcoma. Clinical Cancer Research, 21(14), 3216-3229.
Scopus59 WoS47 Europe PMC462015 Baker, E., Taylor, S., Gupte, A., Sharp, P., Walia, M., Walsh, N., . . . Walkley, C. (2015). BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Scientific reports, 5(1), 10120-1-10120-14.
Scopus106 WoS91 Europe PMC922015 Forristal, C. E., Brown, A. L., Helwani, F. M., Winkler, I. G., Nowlan, B., Barbier, V., . . . Levesque, J. P. (2015). Hypoxia inducible factor (HIF)-2α accelerates disease progression in mouse models of leukemia and lymphoma but is not a poor prognosis factor in human AML. Leukemia, 29(10), 2075-2085.
Scopus33 WoS27 Europe PMC332014 Ahmed, F., Roy Choudhury, N., Dutta, N., Zou, L., & Zannettino, A. (2014). Fabrication and characterisation of an electrospun tubular 3D scaffold platform of poly(vinylidene fluoride-co-hexafluoropropylene) for small-diameter blood vessel application. Journal of Biomaterials Science, Polymer Edition, 25(18), 2023-2041.
Scopus10 WoS8 Europe PMC42014 Noll, J., Hewett, D., Williams, S., Vandyke, K., Kok, C., To, L., & Zannettino, A. (2014). SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia, 16(7), 572-585.
Scopus39 WoS31 Europe PMC382014 Noll, J., Williams, S., Tong, C., Wang, H., Quach, J., Purton, L., . . . Zannettino, A. (2014). Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica, 99(1), 163-171.
Scopus99 WoS78 Europe PMC742014 Richardson, J., Psaltis, P., Frost, L., Paton, S., Carbone, A., Bertaso, A., . . . Worthley, S. (2014). Incremental benefits of repeated mesenchymal stromal cell administration compared with solitary intervention after myocardial infarction. Cytotherapy, 16(4), 460-470.
Scopus22 WoS21 Europe PMC172014 Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Panagopoulos, V., Denichilo, M., . . . Evdokiou, A. (2014). Doxorubicin overcomes resistance to drozitumab by antagonizing inhibitor of apoptosis proteins (IAPS). Anticancer Research, 34(12), 7007-7020.
Scopus9 WoS4 Europe PMC72014 Zinonos, I., Luo, K., Labrinidis, A., Liapis, V., Hay, S., Panagopoulos, V., . . . Evdokiou, A. (2014). Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer. International Journal of Oncology, 45(2), 532-540.
Scopus20 WoS20 Europe PMC162014 Ahmed, F., Dutta, N., Zannettino, A., Vandyke, K., & Choudhury, N. (2014). Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications. Biomacromolecules, 15(4), 1276-1287.
Scopus22 WoS15 Europe PMC82014 Ahmed, F., Choudhury, N., Dutta, N., Brito E Abreu, S., Zannettino, A., & Duncan, E. (2014). Interaction of platelets with poly(vinylidene fluoride-co- hexafluoropropylene) electrospun surfaces. Biomacromolecules, 15(3), 744-755.
Scopus16 WoS16 Europe PMC82014 Hemming, S., Cakouros, D., Isenmann, S., Cooper, L., Menicanin, D., Zannettino, A., & Gronthos, S. (2014). EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem cells, 32(3), 802-815.
Scopus224 WoS189 Europe PMC1762014 Frith, J., Menzies, D., Cameron, A., Ghosh, P., Whitehead, D., Gronthos, S., . . . Cooper-White, J. (2014). Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration. Biomaterials, 35(4), 1150-1162.
Scopus61 WoS50 Europe PMC402013 Ahmed, F., Choudhury, N., Dutta, N., Zannettino, A., & Knott, R. (2013). Near superhydrophobic fibrous scaffold for endothelialization: Fabrication, characterization and cellular activities. Biomacromolecules, 14(11), 3850-3860.
Scopus21 WoS21 Europe PMC112013 Richardson, J., Bertaso, A., Frost, L., Psaltis, P., Carbone, A., Koschade, B., . . . Worthley, S. (2013). Cardiac magnetic resonance, transthoracic and transoesophageal echocardiography: a comparison of invivo assessment of ventricular function in rats. Laboratory Animals, 47(4), 291-300.
Scopus7 WoS6 Europe PMC52013 Frith, J., Cameron, A., Menzies, D., Ghosh, P., Whitehead, D., Gronthos, S., . . . Cooper-White, J. (2013). An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials, 34(37), 9430-9440.
Scopus140 WoS106 Europe PMC842013 Goldschlager, T., Oehme, D., Ghosh, P., Zannettino, A., Rosenfeld, J., & Jenkin, G. (2013). Current and future applications for stem cell therapies in spine surgery. Current Stem Cell Research & Therapy, 8(5), 381-393.
Scopus18 WoS10 Europe PMC82013 Richardson, J., Bertaso, A., Psaltis, P., Frost, L., Carbone, A., Paton, S., . . . Worthley, S. (2013). Impact of timing and dose of mesenchymal stromal cell therapy in a preclinical model of acute myocardial infarction. Journal of Cardiac Failure, 19(5), 342-353.
Scopus45 WoS41 Europe PMC322013 Richardson, J., Nelson, A., Zannettino, A., Gronthos, S., Worthley, S., & Psaltis, P. (2013). Optimization of the cardiovascular therapeutic properties of mesenchymal stromal/stem cells-taking the next step. Stem Cell Reviews, 9(3), 281-302.
Scopus23 WoS22 Europe PMC212013 Vandyke, K., Chow, A., Williams, S., To, L., & Zannettino, A. (2013). Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. British Journal of Haematology, 161(4), 499-507.
Scopus16 WoS18 Europe PMC162013 Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14.
Scopus20 WoS16 Europe PMC192013 Arthur, A., Panagopoulos, R., Cooper, L., Menicanin, D., Parkinson, I., Codrington, J., . . . Gronthos, S. (2013). EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. Journal of Bone and Mineral Research, 28(4), 926-935.
Scopus41 WoS35 Europe PMC322013 Vandyke, K., Fitter, S., Drew, J., Fukumoto, S., Schultz, C., Sims, N., . . . Zannettino, A. (2013). Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: Evidence for site-specific skeletal effects. Journal of Clinical Endocrinology and Metabolism, 98(1), 67-76.
Scopus25 WoS22 Europe PMC222012 Castrechini, N., Murthi, P., Qin, S., Kusuma, G., Wilton, L., Abumaree, M., . . . Kalionis, B. (2012). Decidua parietalis-derived mesenchymal stromal cells reside in a vascular niche within the choriodecidua. Reproductive Sciences, 19(12), 1302-1314.
Scopus31 WoS25 Europe PMC242012 Noll, J., Williams, S., Purton, L., & Zannettino, A. (2012). Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?. Blood Cancer Journal, 2(9), 1-10.
Scopus50 WoS43 Europe PMC442012 Fitter, S., Vandyke, K., Gronthos, S., & Zannettino, A. (2012). Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. Journal of Molecular Endocrinology, 48(3), 229-240.
Scopus55 WoS46 Europe PMC532012 Ghosh, P., Moore, R., Vernon-Roberts, B., Goldschlager, T., Pascoe, D., Zannettino, A., . . . Itescu, S. (2012). Immunoselected STRO-3⁺ mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs: Laboratory investigation. Journal of Neurosurgery: Spine, 16(5), 479-488.
Scopus80 WoS68 Europe PMC522012 Pyragius, C., Georgiou, K., Foster, B., Zannettino, A., & Xian, C. (2012). Microarray expression analysis of genes and pathways involved in growth plate cartilage injury responses and bony repair. Bone, 50(5), 1081-1091.
Scopus51 WoS39 Europe PMC402012 Weber, B., Emmert, M., Behr, L., Schoenauer, R., Brokopp, C., Drogemuller, C., . . . Hoerstrup, S. (2012). Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials, 33(16), 4031-4043.
Scopus75 WoS58 Europe PMC472012 Cakouros, D., Isenmann, S., Cooper, L., Zannettino, A., Anderson, P., Glackin, C., & Gronthos, S. (2012). Twist-1 Induces Ezh2 Recruitment Regulating Histone Methylation along the Ink4A/Arf Locus in Mesenchymal Stem Cells. Molecular and Cellular Biology, 32(8), 1433-1441.
Scopus106 WoS93 Europe PMC842012 Crotti, T., Dharmapatni, A., Alias, E., Zannettino, A., Smith, M., & Haynes, D. (2012). The immunoreceptor tyrosine-based activation motif (ITAM)-related factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints. Arthritis Research & Therapy, 14(6), 1-13.
Scopus47 WoS40 Europe PMC352011 Andersen, D., Kortesidis, A., Zannettino, A., Kratchmarova, I., Chen, L., Jensen, O., . . . Kassem, M. (2011). Development of novel monoclonal antibodies that define differentiation stages of human stromal (mesenchymal) stem cells. Molecules and Cells, 32(2), 133-142.
Scopus12 WoS10 Europe PMC92011 Vandyke, K., Fitter, S., & Zannettino, A. (2011). The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood Cancer Journal, 1(2), E2.
Scopus22 WoS21 Europe PMC102011 Freeman, L., Lam, A., Petcu, E., Smith, R., Salajegheh, A., Diamond, P., . . . Vuckovic, S. (2011). Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8⁺CD4⁺ T cells: evidence from myeloma-bearing mouse model. Journal of Immunology, 187(8), 3987-3996.
Scopus8 WoS8 Europe PMC72011 Martin, S., Diamond, P., Gronthos, S., Peet, D., & Zannettino, A. (2011). The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia, 25(10), 1533-1542.
Scopus108 WoS93 Europe PMC902011 Nath, S., Nicholson, I., Tapp, H., Zola, H., Zannettino, A., & Revesz, T. (2011). Reticulin fibres anchor leukaemic blasts in the marrow of patients with acute lymphoblastic leukaemia. Medical Hypotheses, 77(3), 333-335.
Scopus8 WoS8 Europe PMC62011 Dharmapatni, A., Smith, M., Crotti, T., Holding, C., Vincent, C., Weedon, H., . . . Haynes, D. (2011). TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Research & Therapy, 13(2), R51-1-R51-10.
Scopus38 WoS31 Europe PMC302011 Field, J., Mc Gee, M., Stanley, R., Ruthenbeck, G., Papadimitrakis, T., Zannettino, A., . . . Itescu, S. (2011). The efficacy of allogeneic mesenchymal precursor cells for the repair of an ovine tibial segmental defect. Veterinary and Comparative Orthopaedics and Traumatology, 24(2), 113-121.
Scopus37 WoS40 Europe PMC282011 Arthur, A., Zannettino, A., Panagopoulos, R., Koblar, S., Sims, N., Stylianou, C., . . . Gronthos, S. (2011). EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone, 48(3), 533-542.
Scopus77 WoS70 Europe PMC662011 See, F., Seki, T., Psaltis, P., Sondermeijer, H., Gronthos, S., Zannettino, A., . . . Itescu, S. (2011). Therapeutic Effects of Human STRO-3-Selected Mesenchymal Precursor Cells and their Soluble Factors in Experimental Myocardial Ischemia. Journal of Cellular and Molecular Medicine, 15(10), 2117-2129.
Scopus51 WoS42 Europe PMC412011 Engler, J., Zannettino, A., Bailey, C., Rasko, J., Hughes, T., & White, D. (2011). OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica: the haematology journal, 96(2), 1-33.
Scopus13 WoS12 Europe PMC122011 Goldschlager, T., Ghosh, P., Zannettino, A., Williamson, M., Rosenfeld, J., Itescu, S., & Jenkin, G. (2011). A Comparison of mesenchymal precursor cells and amnion epithelial cells for enhancing cervical interbody fusion in an ovine model. Neurosurgery, 68(4), 1025-1034.
Scopus21 WoS20 Europe PMC202011 Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., . . . Evdokiou, A. (2011). Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. Journal of Bone and Mineral Research, 26(3), 630-643.
Scopus19 WoS18 Europe PMC172011 Psaltis, P., Carbone, A., Leong, D., Lau, D., Nelson, A., Kuchel, T., . . . Worthley, S. (2011). Assessment of myocardial fibrosis by endoventricular electromechanical mapping in experimental nonischemic cardiomyopathy. International Journal of Cardiovascular Imaging, 27(1), 25-37.
Scopus32 WoS28 Europe PMC262010 Goldschlager, T., Ghosh, P., Zannettino, A., Gronthos, S., Rosenfeld, J., Itescu, S., & Jenkin, G. (2010). Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model. Neurosurgical Focus, 28(6), E4-1-E4-8.
Scopus31 WoS23 Europe PMC182010 Ghosh, P., Wu, J., Shimmon, S., Zannettino, A., Gronthos, S., & Itescu, S. (2010). Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cells. Arthritis Research & Therapy, 12(1), R28-1-R28-17.
Scopus47 WoS39 Europe PMC352010 Martin, S., Diamond, P., Williams, S., To, L., Peet, D., Fujii, N., . . . Zannettino, A. (2010). Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica, 95(5), 776-784.
Scopus83 WoS73 Europe PMC582010 Psaltis, P., Paton, S., See, F., Arthur, A., Martin, S., Itescu, S., . . . Zannettino, A. (2010). Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. Journal of Cellular Physiology, 223(2), 530-540.
Scopus132 WoS115 Europe PMC1042010 Engler, J., Frede, A., Saunders, V., Zannettino, A., Hughes, T., & White, D. (2010). Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity. Leukemia, 24(4), 765-770.
Scopus55 WoS52 Europe PMC442010 Vandyke, K., Fitter, S., Dewar, A., Hughes, T., & Zannettino, A. (2010). Dysregulation of bone remodeling by imatinib mesylate. Blood, 115(4), 766-774.
Scopus127 WoS107 Europe PMC882010 Psaltis, P., Zannettino, A., Gronthos, S., & Worthley, S. (2010). Intramyocardial navigation and mapping for stem cell delivery. Journal of Cardiovascular Translational Research, 3(2 Sp Iss), 135-146.
Scopus28 WoS23 Europe PMC182010 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Schultz, C., Sims, N., & Zannettino, A. (2010). The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 25(8), 1759-1770.
Scopus86 WoS73 Europe PMC662010 Zannettino, A., Paton, S., Itescu, S., & Gronthos, S. (2010). Comparative assessment of the osteoconductive properties of different biomaterials in vivo seeded with human or ovine mesenchymal stem/stromal cells. Tissue Engineering. Part A. Tissue Engineering, 16(12), 3579-3587.
Scopus32 WoS29 Europe PMC252010 McCarty, R., Xian, C., Gronthos, S., Zannettino, A., & Foster, B. (2010). Application of autologous bone marrow derived mesenchymal stem cells to an ovine model of growth plate cartilage injury. The Open Orthopaedics Journal, 4(1), 220-226.
Scopus39 Europe PMC392010 Engler, J., Frede, A., Saunders, V., Zannettino, A., White, D., & Hughes, T. (2010). The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells. Blood, 116(15), 2776-2778.
Scopus20 WoS18 Europe PMC142010 Martin, S., Fitter, S., Bong, L., Drew, J., Gronthos, S., Shepherd, P., & Zannettino, A. (2010). NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. Journal of Bone and Mineral Research, 25(10), 2126-2137.
Scopus53 WoS51 Europe PMC452010 Psaltis, P., Carbone, A., Nelson, A., Lau, D., Jantzen, T., Manavis, J., . . . Worthley, S. (2010). Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC: Cardiovascular Interventions, 3(9), 974-983.
Scopus63 WoS52 Europe PMC492010 Menicanin, D., Bartold, P., Zannettino, A., & Gronthos, S. (2010). Identification of a common gene expression signature associated with immature clonal mesenchymal cell populations derived from bone marrow and dental tissues. Stem Cells and Development, 19(10), 1501-1510.
Scopus73 WoS58 Europe PMC522010 Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. (2010). Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: A mechanism for improved insulin sensitivity in Type 2 diabetic CML patients?. Journal of Clinical Endocrinology and Metabolism, 95(8), 3763-3767.
Scopus50 WoS46 Europe PMC432010 Winkler, I., Barbier, V., Wadley, R., Zannettino, A., Williams, S., & Levesque, J. (2010). Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood, 116(3), 375-385.
Scopus199 WoS181 Europe PMC1612010 Williams, S., Martin, S., Vincent, C., Gronthos, S., Zheng, T., Atkins, G., & Zannettino, A. (2010). Circulating levels of TWEAK correlate with bone erosion in multiple myeloma patients. British Journal of Haematology, 150(3), 373-376.
Scopus6 WoS6 Europe PMC42010 Castrechini, N., Murthi, P., Gude, N., Erwich, J., Gronthos, S., Zannettino, A., . . . Kalionis, B. (2010). Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche. Placenta, 31(3), 203-212.
Scopus136 WoS116 Europe PMC952009 Isenmann, S., Arthur, A., Zannettino, A., Turner, J., Shi, S., Glackin, C., & Gronthos, S. (2009). TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells, 27(10), 2457-2468.
Scopus177 WoS166 Europe PMC1492009 Gronthos, S., McCarty, R., Mrozik, K., Fitter, S., Paton, S., Menicanin, D., . . . Zannettino, A. (2009). Heat shock protein-90 beta is expressed at the surface of multipotential mesenchymal precursor cells: Generation of a novel monoclonal antibody, STRO-4, with specificity for mesenchymal precursor cells from human and ovine tissues. Stem Cells and Development, 18(9), 1253-1261.
Scopus71 WoS61 Europe PMC492009 Zinonos, I., Labrinidis, A., Lee, M., Liapis, V., Hay, S., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Molecular Cancer Therapeutics, 8(10), 2969-2980.
Scopus37 WoS38 Europe PMC332009 Arthur, A., Shi, S., Zannettino, A., Fujii, N., Gronthos, S., & Koblar, S. (2009). Implanted adult human dental pulp stem cells induce endogenous axon guidance. Stem Cells, 27(9), 2229-2237.
Scopus129 WoS118 Europe PMC1002009 Paquet- Fifield, S., Schluter, H., Li, A., Aitken, T., Gangatirkar, P., Blashki, D., . . . Kaur, P. (2009). A role for pericytes as microenvironmental regulators of human skin tissue regeneration. Journal of Clinical Investigation, 119(9), 2795-2806.
Scopus181 WoS161 Europe PMC1342009 Vandyke, K., Dewar, A., Menicanin, D., To, L., Hughes, T., Zannettino, A., & Fitter, S. (2009). Imatinib mesylate causes growth plate closure in vivo. Leukemia, 23(11), 2155-2159.
Scopus37 WoS32 Europe PMC342009 Diamond, P., Labrinidis, A., Martin, S., Farrugia, A., Gronthos, S., To, L., . . . Zannettino, A. (2009). Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. Journal of Bone and Mineral Research, 24(7), 1150-1161.
Scopus60 WoS61 Europe PMC462009 Dickinson, M., Prince, H., Kirsa, S., Zannettino, A., Gibbs, S., Mileshkin, L., . . . Joshua, D. (2009). Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal Medicine Journal, 39(5), 304-316.
Scopus42 WoS38 Europe PMC282009 Vandyke, K., Dewar, A., Farrugia, A., Fitter, S., To, B., Hughes, T., & Zannettino, A. (2009). Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 23(5), 994-997.
Scopus49 WoS47 Europe PMC392009 Menicanin, D., Bartold, P., Zannettino, A., & Gronthos, S. (2009). Genomic Profiling of Mesenchymal Stem Cells. Stem Cell Reviews, 5(1), 36-50.
Scopus70 WoS61 Europe PMC442009 Chung, R., Foster, B., Zannettino, A., & Xian, C. (2009). Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate. Bone, 44(5), 878-885.
Scopus61 WoS52 Europe PMC402009 Mc Carty, R., Gronthos, S., Zannettino, A., Foster, B., & Xian, C. (2009). Characterisation and Developmental Potential of Ovine Bone Marrow Derived Mesenchymal Stem Cells. Journal of Cellular Physiology, 219(2), 324-333.
Scopus134 WoS116 Europe PMC962009 Labrinidis, A., Diamond, P., Martin, S., Hay, S., Liapis, V., Zinonos, I., . . . Evdokiou, A. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clinical Cancer Research, 15(6), 1998-2009.
Scopus33 WoS30 Europe PMC282009 Arthur, A., Zannettino, A., & Gronthos, S. (2009). The Therapeutic Applications of Multipotential Mesenchymal/Stromal Stem Cells in Skeletal Tissue Repair. Journal of Cellular Physiology, 218(2), 237-245.
Scopus291 WoS253 Europe PMC1962009 Psaltis, P. J., Carbone, A., Lau, D., Jantzen, T., Williams, K., Sanders, P., . . . Worthley, S. G. (2009). Purkinje fiber injury and electrical remodeling in non-ischemic cardiomyopathy: Implications for sudden cardiac death. EUROPEAN HEART JOURNAL, 30, 558. 2009 Psaltis, P. J., See, F., Paton, S., Martens, T. P., Itescu, S., Worthley, S. G., . . . Zannettino, A. C. W. (2009). STRO-1 immunoselection enhances the biological properties and cardiovascular paracrine effects of bone marrow mesenchymal stromal cells. EUROPEAN HEART JOURNAL, 30, 501. 2008 Zannettino, A., Paton, S., Kortesidis, A., Khor, F., Itescu, S., & Gronthos, S. (2008). Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34-/CD45-/glycophorin-A-bone marrow cells. Haematologica, 92(12), 1707-1708.
Scopus75 WoS66 Europe PMC522008 Psaltis, P., Carbone, A., Nelson, A., Lau, D., Manavis, J., Finnie, J., . . . Worthley, S. (2008). An ovine model of toxic, nonischemic cardiomyopathy-assessment by cardiac magnetic resonance imaging. Journal of Cardiac Failure, 14(9), 785-795.
Scopus25 WoS18 Europe PMC142008 Labrinidis, A., Liapis, V., Thai, L., Atkins, G., Vincent, C., Hay, S., . . . Evdokiou, A. (2008). Does Apo2LTRAIL play any physiologic role in osteoclastogenesis?. Blood, 111(11), 5411-5412.
Scopus19 WoS15 Europe PMC102008 Psaltis, P., Zannettino, A., Worthley, S., & Gronthos, S. (2008). Concise review: Mesenchymal stromal cells: Potential for cardiovascular repair. Stem Cells, 26(9), 2201-2210.
Scopus303 WoS257 Europe PMC2152008 Zannettino, A., Psaltis, P., & Gronthos, S. (2008). Home is where the heart is: Via the FROUNT. Cell Stem Cell, 2(6), 513-514.
Scopus1 WoS1 Europe PMC12008 Fitter, S., Dewar, A., Kostakis, P., To, L., Hughes, T., Roberts, M., . . . Zannettino, A. (2008). Long-term imatinib therapy promotes bone formation in CML patients. Blood, 111(5), 2538-2547.
Scopus146 WoS129 Europe PMC1162008 Zannettino, A., Paton, S., Arthur, A., Khor, F., Itescu, S., Gimble, J., & Gronthos, S. (2008). Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. Journal of Cellular Physiology, 214(2), 413-421.
Scopus482 WoS417 Europe PMC3612007 Gronthos, S., Fitter, S., Diamond, P., Simmons, P., Itescu, S., & Zannettino, A. (2007). A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells. Stem Cells and Development, 16(6), 953-963.
Scopus104 WoS95 Europe PMC802007 White, D., Saunders, V., Dang, P., Engler, J., Venables, A., Zrim, S., . . . Hughes, T. (2007). Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 110(12), 4064-4072.
Scopus280 WoS255 Europe PMC2192007 Isenmann, S., Cakouros, D., Zannettino, A., Shi, S., & Gronthos, S. (2007). hTERT Transcription is repressed by Cbfa1 in human mesenchymal stem cell populations. Journal of Bone and Mineral Research, 22(6), 897-906.
Scopus24 WoS22 Europe PMC152007 Atkins, G., Anderson, P., Findlay, D., Welldon, K., Vincent, C., Zannettino, A., . . . Morris, H. (2007). Metabolism of vitamin D₃ in human osteoblasts: Evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D₃. Bone, 40(6), 1517-1528.
Scopus226 WoS188 Europe PMC1622007 Gronthos, S., & Zannettino, A. (2007). The role of the chemokine CXCL12 in osteoclastogenesis. Trends in Endocrinology and Metabolism, 18(3), 108-113.
Scopus51 WoS41 Europe PMC332006 Gronthos, S., & Zannettino, A. (2006). Potential of bone marrow stromal stem cells to repair bone defects and fractures. Journal of Stem Cells, 1(1), 35-45.
Scopus32006 Tsangari, H., Findlay, D., Zannettino, A., Pan, B., Kuliwaba, J., & Fazzalari, N. (2006). Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patients. Bone, 39(6), 1226-1235.
Scopus19 WoS19 Europe PMC162006 Martin, S., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L., & Zannettino, A. (2006). Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1α in patients with multiple myeloma. Clinical Cancer Research, 12(23), 6973-6977.
Scopus33 WoS30 Europe PMC222006 Atkins, G., Kostakis, P., Vincent, C., Farrugia, A., Houchins, J., Findlay, D., . . . Zannettino, A. (2006). RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. Journal of Bone and Mineral Research, 21(9), 1339-1349.
Scopus115 WoS103 Europe PMC952006 White, D., Saunders, V., Dang, P., Engler, J., Zannettino, A., Cambareri, A., . . . Hughes, T. (2006). OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 108(2), 697-704.
Scopus387 WoS322 Europe PMC2692006 Dewar, A., Farrugia, A., Condina, M., To, L., Hughes, T., Vernon-Roberts, B., & Zannettino, A. (2006). Imatinib as a potential antiresorptive therapy for bone disease. Blood, 107(11), 4334-4337.
Scopus70 WoS65 Europe PMC572006 Martens, T., See, F., Shuster, M., Sondermeijer, H., Hefti, M., Zannettino, A., . . . Itescu, S. (2006). Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nature Clinical Practice Cardiovascular Medicine, 3(Suppl 1), 18-22.
Scopus101 Europe PMC662005 Dewar, A., Zannettino, A., Hughes, T., & Lyons, A. (2005). Inhibition of c-fms by imatinib - Expanding the spectrum of treatment. Cell Cycle, 4(7), 851-853.
Scopus46 WoS45 Europe PMC382005 Zannettino, A., Holding, C., Diamond, P., Atkins, G., Kostakis, P., Farrugia, A., . . . Haynes, D. (2005). Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. Journal of Cellular Physiology, 204(2), 714-723.
Scopus144 WoS141 Europe PMC1032005 Dewar, A., Cambareri, A., Zannettino, A., Boog, B., Doherty, K., Hughes, T., & Lyons, A. (2005). Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood, 105(8), 3127-3132.
Scopus273 WoS248 Europe PMC1982005 Atkins, G., Kostakis, P., Welldon, K., Vincent, C., Findlay, D., & Zannettino, A. (2005). Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Journal of Cellular Physiology, 203(3), 573-582.
Scopus30 WoS29 Europe PMC272005 Kortesidis, A., Zannettino, A., Isenmann, S., Shi, S., Lapidot, T., & Gronthos, S. (2005). Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood, 105(10), 3793-3801.
Scopus338 WoS317 Europe PMC2652005 Zannettino, A., Farrugia, A., Kortesidis, A., Manavis, J., To, L., Martin, S., . . . Gronthos, S. (2005). Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Research, 65(5), 1700-1709.
Scopus184 WoS165 Europe PMC1322004 Zannettino, A., Pan, B., Farrugia, A., Atkins, G., & To, L. (2004). Identification and clinical relevance of receptor activator of nuclear factor kappa B ligand expression of myeloma cells - Reply. Cancer Research, 64(2), 774-775. 2004 Martin, S., To, L., Horvath, N., & Zannettino, A. (2004). Angiogenesis in multiple myeloma: Implications in myeloma therapy. Cancer Reviews: Asia-Pacific, 2(2), 119-129.
2004 Findlay, D., Welldon, K., Atkins, G., Howie, D., Zannettino, A., & Bobyn, D. (2004). The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials, 25(12), 2215-2227.
Scopus193 WoS161 Europe PMC882004 Pan, B., To, L., Farrugia, A., Findlay, D., Green, J., Gronthos, S., . . . Zannettino, A. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone, 34(1), 112-123.
Scopus104 WoS91 Europe PMC712004 Pan, B., Farrugia, A., To, L., Findlay, D., Green, J., Lynch, K., & Zannettino, A. (2004). The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). Journal of Bone and Mineral Research, 19(1), 147-154.
Scopus147 WoS129 Europe PMC1102004 Hu, Y., Zhou, H., Myers, D., Quinn, J., Atkins, G., Ly, C., . . . Ng, K. (2004). Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. Journal of Bone and Mineral Research, 19(1), 89-99.
Scopus45 WoS39 Europe PMC362003 Zannettino, A., Roubelakis, M., Welldon, K., Jackson, D., Simmons, P., Bendall, L., . . . Watt, S. (2003). Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migration. Biochemical Journal, 370(2), 537-549.
Scopus32 WoS31 Europe PMC302003 Zannettino, A., Harrison, K., Joyner, C., Triffitt, J., & Simmons, P. (2003). Molecular cloning of the cell surface antigen identified by the osteoprogenitor-specific monoclonal antibody, HOP-26. Journal of Cellular Biochemistry, 89(1), 56-66.
Scopus37 WoS33 Europe PMC272003 Bendall, L., James, A., Zannettino, A., Simmons, P., Gottlieb, D., & Bradstock, K. (2003). A novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cells. Immunology and Cell Biology, 81(4), 311-319.
Scopus5 WoS4 Europe PMC42003 Haynes, D., Barg, E., Crotti, T., Holding, C., Weedon, H., Atkins, G., . . . Smith, M. (2003). Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology, 42(1), 123-134.
Scopus136 WoS122 Europe PMC962003 Gronthos, S., Zannettino, A., Hay, S., Shi, S., Graves, S., Kortesidis, A., & Simmons, P. (2003). Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. Journal of Cell Science, 116(9), 1827-1835.
Scopus943 WoS8052003 Atkins, G., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., . . . Zannettino, A. (2003). RANKL expression is related to the differentiation state of human osteoblasts. Journal of Bone and Mineral Research, 18(6), 1088-1098.
Scopus218 WoS194 Europe PMC1642003 Farrugia, A., Atkins, G., To, L., Pan, B., Horvath, N., Kostakis, P., . . . Zannettino, A. (2003). Receptor activator of nuclear factor-kB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Research, 63(17), 5438-5445.
Scopus201 WoS185 Europe PMC1482003 Zhang, X., Fitzsimmons, R., Cleland, L., Ey, P., Zannettino, A., Farmer, E., . . . Mayrhofer, G. (2003). CD36/fatty acid translocase in rats: Distribution, isolation from hepatocytes, and comparison with the scavenger receptor SR-B1. Laboratory Investigation, 83(3), 317-332.
Scopus59 WoS51 Europe PMC402003 Gronthos, S., Zannettino, A. C., Hay, S. J., Shi, S., Graves, S. E., Kortesidis, A., & Simmons, P. J. (2003). Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow.. Journal of cell science, 116(Pt 9), 1827-1835.
Europe PMC6692003 Pan, B., To, L., Farrugia, A., Kostakis, P., Atkins, G., Findlay, D., & Zannettino, A. (2003). Multiple myeloma-derived pro-inflammatory cytokines enhance osteoclastogenesis by increasing the number of RANKL-expressing STRO-1 positive osteoprogenitor cells. Blood, 102(11), 5207. 2002 Atkins, G., Bouralexis, S., Evdokiou, A., Hay, S., Labrinidis, A., Zannettino, A., . . . Findlay, D. (2002). Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone, 31(4), 448-456.
Scopus60 WoS60 Europe PMC422002 Atkins, G., Haynes, D., Zannettino, A., Capone, M., Crotti, T., & Findlay, D. (2002). Haemopoietic cells influence stromal cell gene expression during human osteoclast development. Journal of Bone and Joint Surgery - British Volume, 84B(Suppl.3), 235. 2001 Atkins, G., Bouralexis, S., Haynes, D., Graves, S., Geary, S., Evdokiou, A., . . . Findlay, D. (2001). Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone, 28(4), 370-377.
Scopus86 WoS82 Europe PMC641999 Levesque, J. P., Zannettino, A., Pudney, M., Niutta, S., Haylock, D., Snapp, K., . . . Simmons, P. (1999). PSGL-1-mediated adhesion of human hematopoietic progenitors to P-selectin results in supression of hematopoiesis. Immunity, 11(3), 369-378.
Scopus101 WoS94 Europe PMC731999 Gronthos, S., Zannettino, A., Graves, S., Ohta, S., Hay, S., & Simmons, P. (1999). Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. Journal of Bone and Mineral Research, 14(1), 47-56.
Scopus250 WoS230 Europe PMC1891998 Filshie, R. J. A., Zannettino, A. C. W., Makrynikola, V., Gronthos, S., Henniker, A. J., Bendall, L. J., . . . Bradstock, K. F. (1998). MUC18, a member of the immunoglobulin superfamily, is expressed on bone marrow fibroblasts and a subset of hematological malignancies. Leukemia, 12(3), 414-421.
Scopus78 WoS68 Europe PMC611997 Siminons, P., Gronthos, S., Zannettino, A., & Graves, S. (1997). Cell surface antigens expressed by bone marrow stromal cell precursors. Experimental Hematology, 25(8), 736. 1997 Zannettino, A., Aylett, G., Leavesley, D., Pietsch, T., Chang, D., Simmons, P., & Ashman, L. (1997). Specificity and functional effects of antibodies to human stem cell factor. Growth Factors, 14(1), 67-79.
Scopus5 WoS5 Europe PMC51996 Zannettino, A., Rayner, J., Ashman, L., Gonda, T., & Simmons, P. (1996). A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning. Journal of Immunology, 156(2), 611-620.
Scopus41 WoS41 Europe PMC231995 Zannettino, A., Berndt, M., Nuitta, S., Butcher, C., Vadas, M., & Simmons, P. (1995). Primitive human haemopoietic progenitors adhere to P-selectin (CD62P). Blood, 85(12), 3466-3477.
Scopus83 WoS85 Europe PMC431994 Simmons, P. J., Gronthos, S., Zannettino, A., Ohta, S., & Graves, S. (1994). Isolation, characterization and functional activity of human marrow stromal progenitors in hemopoiesis.. Progress in clinical and biological research, 389, 271-280.
Scopus72 Europe PMC381994 Simmons, P. J., Zannettino, A., Gronthos, S., & Leavesley, D. (1994). Potential adhesion mechanisms for localisation of haemopoietic progenitors to bone marrow stroma. Leukemia and Lymphoma, 12(5-6), 353-363.
Scopus98 WoS98 Europe PMC47 -
Book Chapters
Year Citation 2011 Gronthos, S., & Zannettino, A. (2011). Methods for the purification and characterization of human adipose-derived stem cells.. In J. Gimble, & B. Bunnell (Eds.), Methods in Molecular Biology: Adipose-Derived Stem Cells - Methods and Protocols (Vol. 702, 1 ed., pp. 109-120). USA: Humana Press.
DOI Scopus20 Europe PMC172008 Gronthos, S., & Zannettino, A. (2008). A method to isolate and purify human bone marrow stromal stem cells. In D. Prockop, D. Phinney, & B. Bunnell (Eds.), Mesenchymal Stem Cells: Methods and Protocols (Vol. 449, pp. 45-57). United States: Humana Press.
DOI Scopus53 Europe PMC372008 Gronthos, S., & Zannettino, A. (2008). Potential of Bone Marrow Stromal Stem Cells to Repair Bone Defects and Fractures. In P. Koka (Ed.), Progress in Stem Cell Research (pp. 47-62). New York: Nova Science Publishers. 2005 Zannettino, A., Farrugia, A., To, L., & Atkins, G. (2005). An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors. In R. Brown, & P. Joy Ho (Eds.), Multiple Myeloma: Methods and Protocols (Vol. 113, pp. 245-256). Totowa, New Jersey: Humana Press.
DOI Scopus3 -
Conference Papers
Year Citation 2014 Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS12011 Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Diamond, P., Findlay, D., . . . Evdokiou, A. (2011). Local production of osteoprotegerin by breast cancer cells inhibits cancer-induced osteolysis and intra-osseous tumour burden but fails to restrain extra-medullary tumour growth. In BONE Vol. 48 (pp. S256). Athens, GREECE: ELSEVIER SCIENCE INC.
DOI2010 Nath, S. V., Tamblyn, M., Telfer, S., Henwood, T., Gilham, P., Story, C., . . . Revesz, T. (2010). Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory. In BLOOD Vol. 116 (pp. 1062). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12009 McCarty, R. C., Gronthos, S., Zannettino, A. C., Foster, B. K., & Xian, C. J. (2009). Characterisation of ovine bone marrow derived mesenchymal stromal/stem cells and autologous application to growth plate cartilage defect. In BONE Vol. 45 (pp. S106-S107). Cambridge, ENGLAND: ELSEVIER SCIENCE INC.
DOI2009 McCarty, R. C., Gronthos, S., Zannettino, A. C., Foster, B. K., & Xian, C. J. (2009). Characterisation of ovine bone marrow derived mesenchymal stem cells and autologous application to growth plate cartilage defect. In BONE Vol. 44 (pp. S159). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC.
DOI2009 Macsai, C., Hopwood, B., Zannettino, A. C., Scherer, M. A., Foster, B. K., & Xian, C. J. (2009). Micro-CT and micro-array analyses of growth plate cartilage injury responses and bony repair. In BONE Vol. 44 (pp. S152). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC.
DOI2009 Psaltis, P. J., Worthley, S. G., See, F., Itescu, S., Martens, T., Gronthos, S., & Zannettino, A. (2009). Enrichment for Stro-1 Enhances Paracine-mediated Cardiovascular Repair From Human Bone Marrow Mesenchymal Cells. In CIRCULATION Vol. 120 (pp. S821). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS. 2009 Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Lee, M., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression. In BONE Vol. 44 (pp. S54). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC.
DOI2009 Psaltis, P. J., Carbone, A., Manavis, J., Jantzen, T., Lau, D., Sanders, P., . . . Worthley, S. G. (2009). Catheter-based Electromechanical Mapping Accurately Characterizes Segmental Distribution of Left Ventricular Fibrosis in Nonischemic Cardiomyopathy. In CIRCULATION Vol. 120 (pp. S906). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS. 2009 Psaltis, P. J., Zannettino, A., Carbone, A., Manavis, J., Williams, K., Jantzen, T., . . . Worthley, S. G. (2009). Cardiac Repair With Transendocardial Injection of Allogeneic Mesenchymal Precursor Cells for Nonischemic Cardiomyopathy. In CIRCULATION Vol. 120 (pp. S827). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS. 2008 Diamond, P., Labrinidis, A., Martin, S. K., Gronthos, S., To, L., Fuji, N., . . . Zannettino, A. C. W. (2008). Elevated Serum Levels of CXCL12 Is Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S262). Montreal, CANADA: AMER SOC BONE & MINERAL RES. 2008 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel™) Inhibits Oteoclast Activity <i>in Vitro</i> and <i>in Vivo</i> Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY. 2005 Kostakis, P., Atkins, G., Vincent, C., Farrugia, A., Findlay, D., Evdokiou, A., & Zannettino, A. (2005). RANK expression in normal and malignant cells: a monoclonal antibody study. In Journal of Bone and Mineral Research Vol. 20 (pp. SA-259.). Nashville, Tennessee: American Society for Bone and Mineral Research. 2004 Atkins, G., Anderson, P., Welldon, K., Zannettino, A., Morris, H., & Findlay, D. (2004). Vitamin D metabolism in human osteoblasts. In Journal of Bone and Mineral Research Vol. 19 (pp. SA-587). Seattle, Washington: American Society for Bone and Mineral Research. 2003 Kostakis, P., Atkins, G., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., . . . Zannettino, A. (2003). The relationship between RANKL expression and osteoblast differentiation in human osteoblasts. In 30th European Symposium on Calcified Tissues, 8-12 May 2003 Vol. Italy (pp. 314-468). Rome, Italy: Springer Science and Business Media LLC.
DOI2002 Atkins, G., Zannettino, A., Kostakis, P., Pan, B., Farrugia, A., Evdokiou, A., & Findlay, D. (2002). Evidence for the maturation-dependent expression of an osteoclastogenic phenotype in human osteoblasts.. In Journal of Bone and Mineral Research Vol. 17 (pp. S446.). San Antonio, Texas: American Society for Bone and Mineral Research. 2002 Atkins, G., Pan, B., Findlay, D., To, L., Evdokiou, A., Labrinidis, A., . . . Zannettino, A. (2002). Zoledronate is anabolic for human osteoblast-like cells. In Journal of Bone and Mineral Research Vol. 17 (pp. S442.). San Antonio, Texas: American Society for Bone and Mineral Research. -
Conference Items
Year Citation 2014 Cheung, K. C., Hewett, D., Yeung, D., Tan, C. W., To, L. B., & Zannettino, A. (2014). THE ROLE OF MERTK IN THE PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) TO MYELOMA (MM). Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION. 2013 Dharmapatni, A., Coleman, R., Lorimer, M., Zannettino, A., Weedon, H., Wechalekar, M., . . . Crotti, T. (2013). Relationship between Soluble OSCAR and Disease Activity: A 12 Month Study of Newly Diagnosed RA Patients. Poster session presented at the meeting of JOURNAL OF BONE AND MINERAL RESEARCH. Baltimore, MD: WILEY-BLACKWELL. 2012 Crotti, T., Alias, E., Dharmapatni, A., Weedon, H., Zannettino, A., & Smith, M. (2012). EVIDENCE THAT VASCULAR EXPRESSION OF THE ITAM RECEPTOR, OSCAR, IN ACTIVE RHEUMATOID ARTHRITIS IS MODULATED BY INFLAMMATORY MEDIATORS. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY-BLACKWELL. 2008 Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley.
DOI2003 Atkins, G., Anderson, P., Morris, H., Zannettino, A., Kostakis, P., & Findlay, D. (2003). The expression of 25-hydroxyvitaminD 24-hydroxylase and 25-hydroxyvitaminD 1 alpha-hydroxylase in human osteoblasts. Poster session presented at the meeting of Journal of Bone Mineral Research. Minnesota, USA. 2003 Anderson, P., Atkins, G., Morris, H., Kostakis, P., Findlay, D., & Zannettino, A. (2003). The expression of 25-hydroxyvitaminD 24-hydroxylase and 25-hydroxyvitaminD 1 alpha-hydroxylase in human osteoblasts.. Poster session presented at the meeting of Calcified Tissue International. Rome, Italy: Springer. -
Datasets
Year Citation 2004 Hu, Y., Atkins, G., Zhou, H., Myers, D., Quinn, J., Ly, C., . . . Ng, K. (2004). NM_001004419 Homo sapiens C-type lectin domain family 2, member D (CLEC2D), transcript variant 2, mRNA. 2004 Hu, Y., Atkins, G., Zhou, H., Myers, D., Quinn, J., Ly, C., . . . Ng, K. (2004). NM_013269 Homo sapiens C-type lectin domain family 2, member D (CLEC2D), transcript variant 1, mRNA.
Research Funding
Since establishing my laboratory in 2000, I have been awarded in excess of AUD $35 million in funding. Of note, as a CI, I have been awarded a total of 22 NHMRC grants. In addition, I have been awarded competitive grants from Cancer Australia, Leukemia Lymphoma Society (US), Multiple Myeloma Research Foundation, Cancer Council, Australian Cancer Research Fund and the International Myeloma Foundation, as detailed below. Furthermore, I have received industry funding from sources including Mesoblast Ltd, Celgene, Novartis, Zimmer and Johnson & Johnson. A list of the NHMRC, ARC and other awarded grants are provided below.
Grant Title | Funding | Initiative | Role | First Year Funded | Number of Years | Total Amount ($) of Grant |
---|---|---|---|---|---|---|
Bone marrow macrophages: “Resident Evil” in the establishment and progression of multiple myeloma | Research Support | Project Grant | CIA | 2018 | 3 | 570,585.00 |
Myeloma Plasma Cell Dormancy - 'Eradicating the Sleeping Giant' | Research Support | Project Grant | CIB | 2018 | 3 | 834,428.00 |
Tyrosine kinase receptor c-ros-oncogene 1 mediates Twist-1 haploinsufficiency induced craniosynostosis in children: A novel therapeutic target | Research Support | Project Grant | CIB | 2017 | 3 | 562,863.00 |
Targeting skeletal mTORC1 as a novel approach for the treatment of diet-induced insulin resistance |
Research Support |
Project Grant |
CIA |
2016 |
3 |
586,979.00 |
Why is the bone marrow a “hot-spot” for myeloma plasma cell metastasis: are there Gremlins in the system? |
Research Support |
Project Grant |
CIA |
2016 |
3 |
651,979.00 |
The role of ephrinB1 reverse signalling in osteogenic differentiation during skeletal development and osteoporosis |
Research Support |
Project Grant |
CIB |
2015 |
3 |
548,347.00 |
Understanding clonal evolution in multiple myeloma |
Research Support |
Project Grant |
CIA |
2014 |
3 |
647,111.00 |
Twist-1 inhibits MSC osteoblast differentiation during osteoporosis |
Research Support |
Project Grant |
CIB |
2013 |
3 |
466,044.00 |
Is mTOR a novel target for the treatment of osteoporosis? |
Research Support |
Project Grant |
CIA |
2012 |
3 |
543,675.00 |
EphB-ephrinB mediates MSC bone regeneration |
Research Support |
Project Grant |
CIB |
2012 |
3 |
591,010.00 |
The Role of Hypoxia and Myeloma Disease Progression |
Research Support |
Project Grant |
CIA |
2010 |
3 |
594,582.00 |
Twist-1 Regulation of MSC Growth and Development |
Research Support |
Project Grant |
CIB |
2010 |
3 |
594,582.00 |
Novel strategies for the treatment of bone cancer |
Research Support |
Project Grant |
CIC |
2009 |
3 |
456,304.00 |
Control of premature bony fusion in skull development |
Research Support |
Project Grant |
CIC |
2008 |
3 |
555,855.00 |
Role of TWEAK in bone remodelling |
Research Support |
Project Grant |
CIE |
2007 |
3 |
566,947.00 |
The role of factors that regulate early processes of bone cell development |
Research Support |
Project Grant |
CIB |
2007 |
3 |
485,929.00 |
Chemokines and Myeloma Disease Progression |
Research Support |
Project Grant |
CIA |
2007 |
3 |
665,897.00 |
The role of human osteoblasts in osteoclast formation |
Research Support |
Project Grant |
CIC |
2004 |
3 |
436,450.00 |
Skeletal disease mediated by haematological malignancy |
Research Support |
Project Grant |
CIA |
2004 |
3 |
432,750.00 |
The cells and molecules involved in the formation and activity of human osteoclasts |
Research Support |
Project Grant |
CID |
2001 |
3 |
326,036.00 |
Drug resistance in leukaemia |
Research Support |
Project Grant |
CIC |
2001 |
3 |
362,545.00 |
The Molecular Mechanisms of Bone Destruction in Multiple Myeloma |
Research Support |
Project Grant |
CIA |
2001 |
3 |
212,036.00 |
Summary of Other Funding
Grant Title |
Funding |
Source |
Role |
First Year Funded |
Number of Years |
Total Amount ($) of Grant |
Using novel high-precision proteomic analysis to discover biomarkers that identify smouldering myeloma patients at high-risk of progression to active multiple myeloma. |
Research Support |
Cancer Australia - Priority-Driven Collaborative Cancer Research |
CIB |
2020 |
2 |
199,720.00 |
Serum CTX-1 levels to predict smouldering myeloma patients at high-risk of progression to multiple myeloma: a prospective clinical trial |
Research Support |
Bone Health Foundation |
CIB |
2020 |
1 |
25,000.00 |
Targeting Macromolecule Biosynthesis in Cancer by in vivo Flux Measurement of Primary Cells for Rational Drug Development |
Infrastructure Support |
SAHMRI Beat Cancer - Project Infrastructure Grant
|
CID |
2020 |
1 |
87,000.00 |
A new drug delivery system to improve the quality of life and survival of patients with the blood cancer multiple myeloma |
Research Support |
Tour De Cure –Early Career Research Grant |
CIC |
2020 |
1 |
50,000.00 |
N-cadherin inhibitors as vascular disrupting agents: increasing drug delivery to tumours and improving quality of life for cancer patients |
Research Support |
Cancer Australia - Priority-Driven Collaborative Cancer Research Scheme |
CIB |
2019 |
2 |
198,596.00 |
The Role of the Bone Marrow Microenvironment in Myeloma development |
Research Support |
Leukaemia Foundation - National Research Program |
CIA |
2019 |
3 |
596,199.00 |
Investigating the mechanisms by which bone-specific mTORC1 inhibition protects mice against diet-induced insulin resistance |
Research Support |
Diabetes Australia Research Trust |
CIA |
2019 |
1 |
60,000.00 |
ACRF Centre for Integrated Cancer Systems Biology |
Infrastructure Support |
Australian Cancer Research Fund |
CIB |
2019 |
1 |
2,500,000.00 |
Single cell sequencing to discover tumour-associated changes in the bone microenvironment of myeloma patients: identification of prognostic markers and novel therapeutic targets |
Research Support - Brian D. Novis Senior Research Grant |
International Myeloma Foundation |
CIA |
2019 |
1 |
110,000.00 |
Research Consortium Program for Agricultural Product Development |
Research Support |
Premier's Research and Industry Fund |
CIB |
2019 |
5 |
5,214,000.00 |
Stromal Cell-Derived Gremlin1 to Control Multiple Myeloma Disease |
Research Support |
Leukemia and Lymphoma Society |
CIA |
2018 |
3 |
780,000.00 |
The role of novel paediatric B-cell Acute Lymphoblastic Leukaemia (ALL) blast cell-derived factors on blast cell and stromal cell biology |
Research Support |
Women’s and Children’s Health Foundation |
CIA |
2017 |
2 |
201,412.00 |
Adelaide GSEx Flow Cytometry Facility |
Infra-structure Support |
Australian Research Council |
CIC |
2017 |
N/A |
480,000.00 |
Mechanisms governing mobilisation and dissemination in multiple myeloma: the role of hypoxia and the CCR1/CXCR4 axis |
Research Support |
Cancer Australia - Priority-Driven Collaborative Cancer Research Scheme |
CIB |
2017 |
2 |
199,454.00 |
Localized treatment of solid tumours with cytotoxic T cells |
Research Support |
THRF - Project Grant |
CIB |
2017 |
1 |
125,000.00 |
Skeletal endocrine signalling in the regulation of glucose metabolism |
Research Support |
Australian Research Council |
CIA |
2016 |
3 |
379,400.00 |
Validation of a novel therapeutic target in multiple myeloma |
Research Support |
RAHRC - NHMRC Near Miss Grants |
CIA |
2016 |
1 |
100,000.00 |
A Tough Resilin based Hydrogel Platform for Repair and Regeneration |
Research Support |
Australian Research Council |
CIB |
2016 |
3 |
358,000.00 |
Bone Marrow Recovery in Acute Lymphoblastic Leukaemia |
Research Support |
Women’s and Children’s Health Foundation |
CIA |
2015 |
2 |
226,426.00 |
Cooperating genetic changes that drive MM development: the role of SAMSN1 and GLIPR1 tumour suppressor gene |
Research Support |
Cancer Council of South Australia |
CIA |
2015 |
1 |
75,000.00 |
Minimal residual disease (MRD) detection in Multiple Myeloma (MM) patients in complete remission post-autograft: correlation with risk of relapse? |
Research Support |
SA Pathology RAH Contributing Haematologists’ Committee Fund |
CIB |
2015 |
1 |
30,000.00 |
Understanding clonal evolution in multiple myeloma |
Research Support |
Ray and Shirl Norman Trust- HSCGB |
CIA |
2014 |
3 |
300,000.00 |
An improved technology for isolating human adult stem cells for regenerative therapies |
Research Support |
Adelaide Research and Innovation- Commercial Accelerator Scheme Fund |
CIA |
2013 |
1 |
100,000.00 |
Understanding the mechanisms of aberrant bone formation in Saethre-Chotzen syndrome patients with Twist-1 mutations |
Research Support |
Research, Robinson Institute Collaborative Grant |
CIB |
2013 |
1 |
65,000.00 |
South Australian Blood Cancer Tumour Bank |
Infra-structure Support |
SA Cancer Research, Medvet, Community donor |
CID |
2013 |
3 |
980,000.00 |
Australian Cancer Research Foundation South Australian Innovative Cancer Imaging And Therapeutics Facility |
Infra-structure Support |
Australian Cancer Research Foundation |
CIC |
2013 |
1 |
2,800,000.00 |
Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients? |
Research Support |
Cancer Australia and Leukaemia Foundation |
CIA |
2012 |
3 |
528,666.00 |
Does Modifying the bone marrow stromal micro-environment alter the disease course of multiple myeloma? |
Research Support |
Cancer Council of South Australia |
CIA |
2012 |
1 |
99,171.00 |
Efficacy of Targeting the mTOR and PI3 Kinase Pathways as a Treatment Modality for Myeloma |
Industry Research Support |
Novartis Pharma-ceuticals International |
CIA |
2011 |
1 |
65,000.00 |
Development of a Comprehensive Data Base for Myeloma and Related Disorders |
Industry Support |
Celgene Australia |
CIB |
2011 |
2 |
120,000.00 |
Seed Grant for the Establishment of a Multiple Myeloma and Related Disorders Database |
Research Support |
Cancer Council of South Australia |
CIB |
2011 |
1 |
35,000.00 |
Is mTOR a novel target for the treatment of osteoporosis? |
Research Support |
Research, Robinson Institute Collaborative Grant |
CIA |
2011 |
1 |
75,000.00 |
Abl Kinase Inhibition as a Novel Therapy for Myeloma-Associated Bone Loss |
Research Support |
Leukemia & Lymphoma Society - TRP |
CIA |
2009 |
3 |
750,000.00 |
Abl Kinase Inhibition as a Novel Therapy for Malignancy-Associated Bone Loss |
Research Support |
Cancer Council of South Australia |
CIA |
2009 |
1 |
93,000.00 |
Kodak chemiluminescence and gel imaging system (4000MM Pro Image Station).
|
Infra-structure Support |
University of Adelaide/NH&MRC Equipment Grant |
CIF |
2008 |
1 |
55,000.00 |
Tyrosine Kinase Inhibition as a Potential Modality to Control Osteolytic Bone Disease: A New Role for Imatinib Mesylate and Second Generation Bcr-Abl Inhibitors |
Industry Research Support |
Novartis Pharma-ceuticals International |
CIA |
2007 |
3 |
470,000.00 |
Development of Strategies For The Therapeutic Use of Mesenchymal Precursor Cells For Cartilage Repair |
Industry Support |
Mesoblast Ltd |
CIB |
2006 |
2 |
320,692.00 |
Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPC) for the repair of critical size defects in an ovine tibial model |
Industry Support |
Mesoblast Ltd |
CIB |
2006 |
1 |
725,000.00 |
A Preclinical trial of the potential for cultured mesenchymal precursor cells to restore extracellular matrix and normal mechanical function to degenerate intervertebral discs |
Industry/ Research Support |
Mesoblast Ltd/ AusIndustry Grant |
CIC |
2006 |
2 |
794,850.00 |
BIR (Bortezomib Induction and Reinduction) Study |
Clinical Trial and Research Support |
Johnson & Johnson |
CIB |
2006 |
2 |
445,875.00 |
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease? |
Research Support |
Cancer Council South Australia |
CIA |
2005 |
1 |
149,416.00 |
The Use of Aptamer-Based technologies to Identify Immuno-dominant Epitopes of Factor VIII Which are Responsible for the Development of Anti-Factor VIII Antibodies (Inhibitors) |
Research Support |
IMVS-Contributing Haematologist Committee Fund |
CIA |
2005 |
1 |
30,000.00 |
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease? |
Research Support |
Royal Adelaide Hospital-IMVS Research Fund-Clinical Project Grants |
CIA |
2004 |
1 |
23,500.00 |
Mechanisms of Increased Microvessel Density (MVD) In Multiple Myeloma |
Research Support |
IMVS-Contributing Haematologist Committee Fund |
CIA |
2004 |
1 |
36,000.00 |
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease? |
Research Support |
RAH/IMVS Clinical Research Grants |
CIA |
2004 |
1 |
18,500.00
|
Utilisation of human osteoblast and osteoclast co-culture models to study anti-resorptive and anabolic agents |
Industry Support |
Ely Lilly |
CIC |
2004 |
1 |
15,000.00 |
Research and Services Agreement |
Industry/Research Support |
Angioblast Ltd/ Mesoblast Ltd |
CIB |
2003 |
3 |
300,000.00 |
The Efficacy of Mesenchymal Precursor Cells to Repair Cardiac Defects |
Industry Support |
Angioblast Systems, Ltd |
CIA |
2003 |
2 |
100,000.00 |
Characterisation of RANKL and OPG production by human osteoblastic cells |
Industry Support |
Ely Lilly |
CIB |
2002 |
1 |
20,000.00 |
Tantalum and osteointegration |
Industry Support |
Zimmer |
CIC |
2002 |
1 |
45,000.00 |
Novel Interaction of the Epidermal Growth Factor-Like Protein DLK with the Growth Arrest-Specific Gene Product GAS-1: Implications for Adipocyte Differentiation |
Research Support |
IMVS/RAH Research Fund |
CIB |
2001 |
1 |
11,000.00 |
Characterisation of Novel Drug-Resistance Proteins in Human Leukaemic Cells |
Industry Support |
Medvet Pty Ltd |
CIC |
2000 |
1 |
110,000.00 |
The Identification and Characterization of Novel Regulators of Mesenchymal Stem Cell Differentiation and Lineage Commitment |
Industry Support |
Zymogenetics Inc., Seattle, Washington |
CIA |
1999 |
1 |
90,000.00 |
As a supervisor/mentor, I aim to provide an environment that:
- Promotes strategic, independent, creative and critical scientific thinking;
- Encourages a strong work ethic and a disciplined approach;
- Supports the development of rigor in experimental design;
- Encourages a sense of project ownership;
- Promotes confidence and leadership;
- Encourages effective interpersonal skills; and
- Teaches effective written and verbal communication skills.
Teaching:
As a former full-time Medical Scientist in the Department of Haematology, SA Pathology/Institute of Medical and Veterinary Science and Level E Affiliate Titleholder in the School of Medicine, Faculty of Health Science, University of Adelaide, I provided leadership in teaching and supervision in my daily interactions with post-doctoral scientists, research assistants, undergraduate, graduate and post-graduate students. Furthermore, during this period, I provided numerous guest lectures (BBTech students, Uni SA; BHlthSci and MBBS, Uni Adelaide) and successfully mentored numerous honours, masters, PhD and medical students (as part of Department of Medicine’s 4th Year Research Program).
In addition to graduate and post-graduate teaching, since joining the University of Adelaide as Professor of Experimental Haematology, I present undergraduate lectures in courses offered by the Faculty of Health and Medical Science ([FHMS] Medicine, Physiology, Anatomy and Pathology and Dentistry), Faculty of Science ([FS] Masters program, stem cells) and the University of Sydney (tissue engineering). I provide Honours workshops relating to thesis writing, career opportunities and career development. I also host Physiology III (BHlthSci, FHMS) and Principals and Practice of Research III (BSc Advanced, FS) students in my laboratory for small group discovery and research training.
My abilities as a post-graduate educator and supervisor are manifest in the following outcomes:
- Completions - 100% student completions
- Awards for Excellence - Former students have received awards for excellence, including the University Medal (S Martin), Hugh Gilmore Prize (P Psaltis), Ross Wishart Memorial Award (P Psaltis), Nimmo Prize (P Psaltis), Hanson Institute Clinical Researcher of the Year Award for 2009 (D Harland/White), HSANZ Albert Baikie Memorial Medal (S Martin).
- Post-Graduate Placements - Former students have been appointed to post-doctoral positions in prestigious institutions including Mt Sinai Hospital, NY (B Pan), Mayo Clinic, MN (P Psaltis), St Jude’s Hospital, TN (J Engler) or have gone onto significant positions in local institutions (D Harland/White, H Tsuji and C Oh).
- Publications and Presentations - All past and present students have presented their findings at international and national scientific meetings, including oral presentations at major international conferences (American Society of Haematology, American Heart Association) and have published articles in highly cited and prized scientific journals (BLOOD, Cell Stem Cells, JACC), including featured articles in BLOOD, JBMR and JCEM.
Mentoring:
Post-Doctoral Scientist, Research Staff and Peer Training:
I currently supervise 8 post-doctoral scientists (Dr Duncan Hewett, Dr Stephen Fitter, Dr Sally Martin, Dr Kate Vandyke, Dr Jacqueline Noll, Dr Mel Cantley, Dr Bill Panagopoulos; Dr Krzysztof Mrozik), 3 Clinical Research Fellows (Dr Angie Yong, Dr Stanley Cheung, Dr Cindy Lee), 3 Research Assistants (Elyse Bell, Alanah Bradey, Rosa Harmer) and 2 technical officers (Mrs Vicki Wilczek and Mrs Lynda Saunders). Dr Kate Vandyke (Beat Cancer ECR Fellow), Dr Jacqueline Noll (Veronika Sacco Clinical Research Fellow), Dr Bill Panagopoulos (NHMRC ECR Fellow) and Dr Mel Cantley (NHMRC ECR Fellow) are self-funded research fellows, while the remainder of the staff are employed on peer reviewed, competitively awarded grants and industry funds. I advise post-doctoral staff in relation to their long-term career plans; aid with identifying independent research opportunities and encourage their supervision of students. This ensures that postdoctoral staff play an intrinsic role in the “education cycle” and possess the necessary skills for a successful independent research career.
Other Contributions to the Training/Mentoring Process:
In addition to graduate/post-graduate teaching, I also contribute to the formal education process by assessing honours and PhD theses. To date I have assessed in excess of 45 honour theses and 12 PhD theses from local, national and international Universities.
As an inaugural member of the Medical and Scientific Advisory Group (MSAG) of Myeloma Australia (http://www.myeloma.org.au) I contribute to the community’s and clinician’s awareness about myeloma. Furthermore, the MSAG provide guidance on both myeloma and supportive treatment strategies and have co-authored guidelines for the safe use of bisphosphonates (Dickinson M et al, Intern Med J. 2009. May;39(5):304-16; Lee et al., 1. Intern Med J, 47(8), 938-951.) and Multiple Myeloma Clinical Practice Guidelines (coordinated on behalf of the MFA-MSAG by Quach and Prince et al).
I also present lectures to a wide variety of organisations including Rotary Australia, The University of the Third Age, The Greek Women’s Philanthropic Society, The Australian Asian Women’s Association and Myeloma SA (a support group comprised of myeloma sufferers and their carers). I also host numerous guided, interactive tours of the Cancer Theme facilities at the SAHMRI (approximately 10 per year). These community engagement opportunities serve to raise the awareness of research activities being conducted at SAHMRI and the UA.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2023 Co-Supervisor Investigating mechanisms of relapse in high-risk paediatric pre-B-cell acute lymphoblastic leukaemia Doctor of Philosophy Doctorate Full Time Mr Caleb Ben Lill 2022 Co-Supervisor Lipidomic and metabolomic profiling of the bone marrow microenvironment to understand multiple myeloma disease development Doctor of Philosophy Doctorate Part Time Miss Mackenzie Rose Skinner 2022 Co-Supervisor Genetic and biochemical characterisation of the SIK3 mutation, R393H: A causal mutation that helps define a new family of human monogenetic disorders Doctor of Philosophy Doctorate Full Time Eliana Gloria Stanziano 2022 Co-Supervisor Modelling neurotoxicities following paediatric cancer treatments to improve cognitive outcomes and quality of survival Doctor of Philosophy Doctorate Full Time Miss Maya Rochelle Davies 2021 Co-Supervisor Interventions and Novel Treatments for Obesity-associated Pathologies Doctor of Philosophy Doctorate Full Time Miss Alanah Loretta Bradey 2021 Principal Supervisor Mechanisms of bortezomib-induced gut dysfunction and novel strategies to mitigate its impact in people with multiple myeloma. Doctor of Philosophy Doctorate Full Time Miss Jacqui Steele Scott 2021 Co-Supervisor Targeting the bone marrow microenvironment: exploring Gremlin1’s role in myeloma-associated macrophages and developing IMiD-sensitive murine models of myeloma Doctor of Philosophy Doctorate Full Time Miss Emma Anna-Jane Cheney 2020 Co-Supervisor Changes in the bone marrow microenvironment with progression to multiple myeloma Doctor of Philosophy Doctorate Part Time Miss Laura Joy Trainor 2020 Co-Supervisor Identification of novel mechanisms that drive the dissemination of multiple myeloma tumour cells Doctor of Philosophy Doctorate Full Time Miss Hayley Bridget Parkinson -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2021 - 2025 Co-Supervisor Elucidating the pro-tumorigenic role of myeloperoxidase in multiple myeloma and its potential as a novel therapeutic target Doctor of Philosophy Doctorate Full Time Mr Connor Maxwell Douglas Williams 2019 - 2023 Co-Supervisor A Novel Antibiofilm Treatment for Surgical Site Infections Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Mrs Laurine Dorothea Kaul 2019 - 2023 Principal Supervisor The TAM receptor family in multiple myeloma Doctor of Philosophy Doctorate Full Time Miss Justine Rachel Clark 2019 - 2023 Principal Supervisor The Role of Bone Marrow Mesenchymal Stromal Cell Senescence in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Natalya Plakhova 2017 - 2020 Co-Supervisor CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance Doctor of Philosophy Doctorate Full Time Miss Mara Natasha Zeissig 2017 - 2020 Co-Supervisor Generation and Transcriptomic Analysis of HIF-1Alpha and HIF-2Alpha Knockout 5TGM1 Multiple Myeloma Cells Master of Philosophy Master Full Time Dr Yu Chinn Joshua Chey 2017 - 2020 Principal Supervisor The Role of Osteoblast-mTORC1 in the Regulation of Glucose Metabolism Doctor of Philosophy Doctorate Full Time Miss Pawanrat Tangseefa 2017 - 2021 Principal Supervisor Macrophages, Myeloma, Mouse Models and Methodologies Doctor of Philosophy Doctorate Full Time Mrs Khatora Shanae Opperman 2015 - 2019 Co-Supervisor Smart Materials for Cartilage and Bone Tissue Engineering Doctor of Philosophy Doctorate Full Time Mr Jiabin Zhang 2015 - 2019 Principal Supervisor The Role of SAMSN1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Ms Natasha Friend 2015 - 2020 Principal Supervisor The Role of Gremlin1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mrs Kimberley Claire Clark 2014 - 2018 Principal Supervisor A Genomic Approach Towards an Understanding of Clonal Evolution and Disease Progression in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Ankit Kumar Dutta 2013 - 2017 Principal Supervisor The Role of TWIST1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Chee Man Cheong 2012 - 2018 Principal Supervisor N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mr Krzysztof Mrozik 2011 - 2014 Co-Supervisor Mesenchymal Stem Cells for the Treatment of Myocardial Infarction-Induced Ventricular Dysfunction Doctor of Philosophy Doctorate Full Time Dr James David Richardson 2011 - 2018 Co-Supervisor Investigating the Role of HIF-1 and HIF-2 Transcription Factors in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Natalia Magdalena Martin 2010 - 2018 Principal Supervisor The Role of mTORC1 in Mesenchymal Stem Cell Fate Determination, Osteoblast Differentiation and Skeletal Development Doctor of Philosophy Doctorate Part Time Ms Mary Patricia Matthews 2009 - 2013 Co-Supervisor The Role of TWIST-1 in the Regulation of Mesenchymal Stem Cell Growth, Fracture Repair and Bone Loss Doctor of Philosophy Doctorate Full Time Mr Lachlan Cooper 2007 - 2011 Co-Supervisor Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Jane Engler 2007 - 2010 Principal Supervisor The Effects of Tyrosine Kinase Inhibition on Bone Remodelling Doctor of Philosophy Doctorate Full Time Dr Kate Vandyke 2006 - 2010 Co-Supervisor The Cardiovascular Reparative Properties of Bone Marrow Mesenchymal Precursor Cells Doctor of Philosophy Doctorate Full Time Prof Peter Psaltis 2005 - 2009 Principal Supervisor Molecular and Cellular Mechanisms of Increased Angiogenesis in Multiple Myeloma: A Role for CXCL12 Doctor of Philosophy Doctorate Full Time Dr Sally Martin 2005 - 2012 Co-Supervisor Cellular and Molecular Mechanisms Involved in the Repair of the Injured Growth Plate in Young Rats Doctor of Philosophy Doctorate Full Time Ms Carmen Macsai 2004 - 2008 Co-Supervisor Factors which Impact on the Response of CML Patients to ABL Kinase Inhibitor Therapy: A Study of Imatinib and Nilotinib Doctor of Philosophy Doctorate Part Time Prof Deborah Lee White 2002 - 2004 Principal Supervisor Mechanisms of Skeletal Disease Mediated by Haematological Malignancies Doctor of Philosophy Doctorate Full Time Miss Beiqing Pan 2001 - 2002 Principal Supervisor CLINICAL MEDICINE Master of Medical Science Master Full Time Miss Beiqing Pan
-
Board Memberships
Date Role Board name Institution name Country 2020 - 2020 Member Ministerial Advisory Board - Health and Medical Industries Department of Industry and Skills, Government of South Australia Australia 2020 - ongoing Member Ministerial Implementation Board – Health and Medical Industries Department of Industry and Skills, Government of South Australia Australia 2019 - ongoing Member Board Health Translation SA (HTSA) Australia 2019 - ongoing Member Board Adelaide BioMed City Australia 2015 - 2019 Member Board of Directors Colgate Australian Clinical Dental Research Centre, University of Adelaide Australia 2014 - ongoing Member Advisory Board Robinson Research Institute (RRI), University of Adelaide Australia -
Committee Memberships
Date Role Committee Institution Country 2019 - ongoing Chair Research Advisory Committee Adelaide BioMed City Australia 2016 - ongoing Member ARCPOH Expert Advisory Committee University of Adelaide Australia 2014 - 2018 Member NHMRC Assigners Academy National Health and Medical Research Council Australia 2014 - 2015 Chair Research Committee, School of Medical Science University of Adelaide Australia 2012 - ongoing Member Bioscience Pillar Committee South Australian Health and Medical Research Institute (SAHMRI) Australia 2012 - 2012 Member Robinson Institute Transition Management Committee University of Adelaide Australia 2012 - 2012 Member Leukaemia Foundation National Research Program Assessment Panel Leukaemia Foundation Australia 2011 - 2011 Member Reshaping the Robinson Task Force, Robinson Institute University of Adelaide Australia 2010 - 2015 Member Scientific Advisory Committee Bone Health Foundation Australia 2010 - 2013 Member Fellowships and Scholarships Committee Leukaemia Foundation of Australia Australia 2009 - 2012 Member Medical Assessment Classification Committee SA Pathology Australia 2007 - 2012 Co-Chair Institutional Biosafety Committee SA Pathology/Institute of Medical and Veterinary Science Australia -
Memberships
Date Role Membership Country 2019 - ongoing Member Beat Cancer Project Executive Management Group Australia 2012 - ongoing Member Cell Reprogramming Australia (CRA) Australia 2010 - ongoing Member Centre for Personalised Cancer Medicine, University of Adelaide Australia 2010 - ongoing Member Centre for Stem Cell Research, University of Adelaide Australia 2010 - ongoing Member Centre for Cancer Biology, SA Pathology Australia -
Offices Held
Date Office Name Institution Country 2020 - ongoing Non-executive director AusHealth Pty Ltd Australia 2012 - 2012 Cancer Biology and Oncology GRP National Health and Medical Research Council Australia 2010 - 2010 Oncology GRP National Health and Medical Research Council Australia 2006 - ongoing Cell Biology GRP National Health and Medical Research Council Australia -
Review, Assessment, Editorial and Advice
Date Title Type Institution Country 2018 - 2019 NHMRC Ideas Grant Review Panel Grant Assessment National Health and Medical Research Council Australia 2013 - 2017 Subject Matter Expert and Assessor, Science and Industry Endowment Fund (SIEF) Grant Assessment CSIRO Australia 2010 - 2010 Subject Matter Expert, Facilities and Laboratory Operations Advice South Australian Health and Medical Research Institute Australia 2006 - ongoing Medical and Scientific Advisory Group Advice Myeloma Foundation of Australia Australia
Connect With Me
External Profiles